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Tau protein is involved in a number of distinct neurodegenerative disorders called 
tauopathies, which include one of the major leading causes of death in the world, 
Alzheimer’s disease. Over the past years, many in vitro and in vivo studies helped 
elucidating the main events leading to the spreading of the pathology and brain 
degeneration; however, the detailed molecular mechanisms underlying each step are 
yet to be discovered. Intracellular tau aggregates diffuse in the brain following 
anatomic connections, and their spreading is the result of the combination of 
extracellular release, uptake and seeding of the endogenous protein in receiving cells. 
Many molecular partners mediating tau internalization have been identified, but many 
others are still elusive. In particular, it would be worth investigating if different 
neurodegeneration-related amyloids (i.e. tau, a-synuclein, amyloid-b) might share a 
common pathway mediating their toxicity and cell-to-cell spreading.  
 
In this PhD thesis, we analysed the contribution of the cellular prion protein (PrPC) to 
the internalization of tau fibrils. We took advantage of the methodology extensively 
described in the literature to produce synthetic amyloids made of the truncated form 
of tau protein named K18, consisting only of the microtubule-binding domains of the 
protein. We compared the uptake of K18 fibrils in two mouse neuroblastoma cell lines: 
wild-type N2a cells and N2a cells that had been knocked-out for PrPC (N2a KO). Our 
results indicate that the number of internalized amyloids is higher in N2a cells 
expressing PrPC compared to their knocked-out counterpart, suggesting that the prion 
protein might be one of the many uptake mechanisms. Indeed, the absence of PrPC 
does not block completely the entrance of tau fibrils in the cytoplasm. This 
phenomenon is mediated by the binding between tau fibrils and the prion protein, and 
configures itself as a mutual interaction: while PrPC promotes a higher internalization 
of the amyloids, the presence of tau fibrils leads to an increase in the total levels of 
PrPC, which accumulates on the cell membrane. Although it is not yet clear if this 
effect is be tau-driven or a simple side-effect, it might be responsible for a more 
sustained internalization rate. Subsequently, we used monoclonal antibodies directed 
against the different domains of PrPC in order to evaluate their role in the uptake 
process. What we found is that both the targeting of the N-terminus and of the 
hydrophobic region negatively affect the internalization of tau K18 amyloids, while the 
globular domain does not seem to play a role, at least not in the specific region we 
considered. 
 
As the prion protein exists also in the pathological conformation PrPSc, we analysed 
its interaction with K18 fibrils using prion-infected neuroblastoma cell lines (ScN2a). 
The exposition of ScN2a cells to K18 amyloids resulted in a strong decrease of the 
PK-resistant  
PrP levels, independently of the type of replicating strain (RML or 22L prion strains). 
We hypothesize that K18 fibrils might bind either to PrPSc or, more probably, to PrPC 
 2 
and thus prevent prion replication. Indeed, neither macroautophagy nor lysosomes 
were found to be overactivated as a consequence of the treatment.  
 
In conclusion, our findings point towards a role for PrPC in the regulation of the cell-
to-cell transfer of tau amyloids. Additionally, this study focuses on the molecular 
mechanisms of the relationship between tau aggregates and the pathological PrPSc. 
The co-presence of tau and prion pathologies has a clinical relevance, as it is a 
common feature of a subgroup of prion disorders characterised by a longer disease 









































Aß: amyloid-ß protein 
AD: Alzheimer’s disease 
AGD: Argyrophilic grain disease 
ALS: amyotrophic lateral sclerosis 
APLP1: apolipoprotein 1 
APOE: apolipoprotein E 
APP: amyloid precursor protein 
Asn: asparagine 
BSE: Bovine Spongiform Encephalopathy 
CBD: Corticobasal Degeneration 
CDK 5: cyclin-dependent kinase 5 
CJD: Creutzfeldt-Jakob Disease 
CNS: Central Nervous System 
CWD: Chronic Wasting Disease 
CC1: charged cluster 1 
CC2: charged cluster 2 
Cys: cysteine 
DIAD: Dominantly inherited Alzheimer’s Disease 
DLB: Dementia with Lewy Bodies 
Dpl: Doppel 
EM: Electron microscopy 
ER: endoplasmic reticulum 
ERAD: Endoplasmic reticulum associated protein degradation 
fCJD : familial CJD  
FFI: fatal familial insomnia  
FRET: Fluorescence Resonance Energy Transfer 
FSE: Feline Spongiform Encephalopathy 
FTLD: Frontotemporal Lobar Degeneration 
FTDP-17: Frontotemporal dementia with parkinsonism linked to chromosome 17 
GGT: globular glial tauopathy  
GGIs: globular glial inclusions 
GPI anchor: glycosylphosphatidylinositol anchor.  
GSK3ß: Glycogen synthase kinase 3 beta 
GSS: Gerstmann-Sträussler-Scheinker disease  
HPSGs: heparan sulfate proteoglycans 
LAG3: Lymphocyte activation gene 3 
LB:   Lewy Bodies 
MAPT: microtubule-associated protein tau 
mGluR5: metabotropic glutamate receptor 5  
MSA: Multiple System Atrophy 
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MT: microtubule 
NCAM: neural cell adhesion molecule  
NFTs: neurofibrillary tangles 
NMDAR: N-methyl-D-asparthate receptor 
NMR: nuclear magnetic resonance 
OR: octarepeat region 
ORF: Open Reading Frame 
PD:    Parkinson’s disease 
PHFs: paired helical filaments 
PiD: Pick’s disease 
PK: proteinase K 
PKA: protein kinase A 
PP2A: protein phosphatase 2 A 
PrPC = cellular prion protein 
PrP-CAA: prion protein cerebral amyloid angiopathy 
PrPSc : scrapie prion protein 
PSEN: presenilin 
PSP: Progressive Supranuclear Palsy 
PSP-CBS: Progressive Supranuclear Palsy with Corticobasal Syndrome 
RPTPα: protein tyrosine phosphatase alpha 
sCJD: sporadic CJD 
SFs: straight filaments 
SNpc: substantia nigra pars compacta 
SOD-1: superoxide dismutase-1 
SUMO small ubiquitine-like protein 
Tau-RD: repeated domains of tau 
TDP-43: TAR DNA Binding Protein 43 
ThS: thioflavin S 
TME: Transmissible Mink Encefalopathy 
TSE: Transmissible Spongiform Encephalopathy 
UPS: ubiquitine-proteasome system 
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1.1. Neurodegenerative disorders  
 
The selective degeneration of specific subsets of neurons is a common feature of a 
variety of different disorders grouped under the umbrella term “neurodegenerative 
diseases”. Although they display unique neuropathological characteristics, and are 
therefore considered as independent identities, emerging evidence proposes that 
very similar molecular pathways are involved in the progression of all these disorders, 
and that they are in the end all different faces of the same coin. Specifically, the 
aggregation and subsequent deposition of the abnormally folded proteins involved in 
each disease follow a common mechanism, called “prion-like” after its first 
identification as the behaviour of the prion protein in prion disorders. In vitro and in 
vivo studies showed that, to a different extent, all these proteins can act as seeds and 
template the aggregation of the endogenous protein into insoluble fibrils. In this 
section, we will give an overview of the most common neurodegenerative disorders, 
with a special focus on tauopathies and on their prion-like properties. 
 
 
Table 1.1. Classification of the most common neurodegenerative disorders and the proteins 
involved in the diseases. 
 
 
 1.1.1. Parkinson’s disease and synucleinopathies  
 
PD is the second most common neurodegenerative disease after AD and affects 
people around 65 years of age, with a higher prevalence in men [1]. Contrary to AD, 
PD configures mainly as a movement disorder, and dementia may be not present in 
all cases. Motor symptoms are caused by the progressive degeneration of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and include 
bradikynesia, tremors, rigidity, postural instability. Non-motor symptoms, when 
present, can be observed years before the actual onset of the disease [2], suggesting 
that the actual pathology has a long prodromal phase that could be exploited to gather 
an early diagnosis and block the disease.  
The etiology of PD is mainly sporadic, but it can also have genetic [3-6] and 
environmental origin (i.e. exposure to some environmental toxins, paraquat and the 
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pesticide rotenone) [7, 8]. In all cases, the major hallmark is the deposition of 
aggregated forms of the protein a-synuclein into structures known as Lewy Bodies 
(LB) [9, 10]. The pattern of spreading of LB is disease-specific and allows the 
discrimination between different pathologies all characterised by the presence of a-
synuclein amyloids. In PD, LB localize mainly in the cell cytoplasm of the neurons in 
the substantia nigra in the form of brainstem-type LB. Pathology starts in cholinergic 
and monoaminergic brainstem neurons and in the olfactory system, and expands to 
the limbic and neocortical brain regions as disease progresses. Patients affected by 
Dementia with Lewy Bodies (DLB) accumulate LB in the temporal lobe, while in 
Multiple System Atrophy (MSA) synuclein aggregates are found in glial cells to form 
cytoplasmic inclusions. The localization of the amyloids, as well as their intrinsic 
conformations, are thought to be responsible for the different disease phenotypes. 
Several studies showed the ability of PD- and MSA-derived seeds to faithfully 
propagate their conformation in sequential passages both in cells and in mice, 




The aberrant deposition of tau protein results in the instauration of a complex array of 
disorders, grouped under the name of Frontotemporal Lobar Degeneration-Tau 
(FTLD-Tau). FTLD is defined as the degeneration of the frontal and temporal lobes of 
the brain that may eventually lead to language impairment, behavioural and 
personality changes[11]. Non-Tau FTLD include other disorders with different 
aggregated proteins: FTLD-TDP, FTLD-FET and FTLD-UPS (fig). FTLD-TDP is the 
most common type, accounting for around 50% of total cases. FTLD-Tau is slightly 
less common, with a prevalence of around 40%, while FTLD-FET and FTLD-UPS are 




Fig. 1.1. Molecular classification of frontotemporal lobar degeneration according to the type of 





FTLD associated with tau deposits comprises a variety of clinically and biochemically 
different disorders, collectively called tauopathies. While all these diseases have in 
common the accumulation of abnormal tau aggregates in the brain, many factors play 
a role in discriminating among neuropathological phenotypes: the involvement of 
different anatomical regions, the cell types affected, and the presence of distinct tau 
isoforms in the pathological aggregates. AD is the most common degenerative 
dementia showing neuronal tau pathology; however, since the accumulation of 
intracellular neurofibrillary tangles of tau is accompanied by the presence of 
extracellular deposits of Aß, AD is classified as a secondary tauopathy, as other 
proteins are involved in the pathogenesis. Primary tauopathies see only tau as the 
major player in the disease aetiology, and comprise Pick’s disease (PiD), corticobasal 
degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain 
disease (AGD), frontotemporal dementia and parkinsonism linked to chromosome 17 
(FTDP-17) and the recently characterised globular glial tauopathy (GGT) [13] 
FTLD-Tau pathologies may have either a genetic or sporadic etiology. All the genetic 
cases go under the name of Frontotemporal Dementia with Parkinsonism linked to 
chromosome 17 (FTDP-17), and are due to the presence of mutations in the MAPT 
gene. Indeed, it was only after the discovery of FTDP-linked mutations in 1998 that 
the idea that tau alone could cause neurodegeneration became widely accepted [14]. 
To date, more than 38 mutations in the MAPT gene are associated with FTDP 
syndromes [15], with some genetic cases that partially or completely phenocopy the 
aforementioned sporadic tauopathies [16].This evidence implies that the study of tau 
mutations and their functional consequences can provide useful insights also in the 
pathogenesis of the non-genetic cases of tauopathies.  
Tau protein exists in two subclasses of isoforms characterised by the presence of 
either 3 (3R) or 4 (4R) repeated regions constituting the microtubule-binding domain. 
In the physiological state, the ratio between the expression of 3R and 4R tau is around 
1:1, and it is kept under strict control by regulatory mechanisms. Indeed, the 
dysregulation of this equilibrium and the subsequent over-representation of one of the 
two subclasses is the most common feature of tauopathies, both genetic and 
sporadic. For example, it has been shown that the MAPT locus exists in two 
haplotypes, either with a 900 kb inversion (H1) or non-inversion (H2) polymorphism 
[17].The inheritance of H1/H1 genotype is considered a risk factor for developing PSP 
and CBD [18], as the sequence inversion alters the splicing and results in a higher 
production of 4R transcripts and in an increased 4R:3R ratio.  
Pathogenic mutations interest mainly the exons 9-13 of the coding region, or the 
splice-donor site of the intron following the alternatively spliced exon 10. Two more 
pathological mutations with effect on MT binding activity of tau (R5H and R5L) were 
identified in exon 1 [19, 20]. Those located in exons 1, exon 9, exons 11-13 affect all 
six tau isoforms, while those in exon 10 have their effect only on 4R- tau isoforms [15]. 
Tau mutations can be functionally divided into two, partially overlapping classes: 
mutations whose effect is at the protein level, and mutations that affect the alternative 
splicing of the pre-mRNA. Some mutations such as N296H, ∆N296 and ∆K280 [21, 
22] have effects at both levels, and are located in exon 10 of the tau gene. No 
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mutations leading either to a truncated protein or the nonsense-mediated decay of 
the mRNA have been identified. 
Type and localization of tau mutations determine, to a certain extent, the 
morphologies of the filaments and their isoform composition. Mutations that promote 
the inclusion of exon 10 lead to the formation of wide twisted ribbon-like filaments 
composed only by 4R-tau present in both glial and nerve cells. Missense mutations 
in exon 10 that do not affect splicing result in the formation of narrow twisted ribbons, 
composed of 4R-tau isoforms and present both in neurons and to a lesser extent in 
glia. Mutations that lie in the coding region outside exon 10 cause a pathology that is 
primarily neuronal. 
Sporadic FTLD-tau pathologies might be discriminated by the type of isoform that 
accumulates in the brain: 3R tau, 4R tau or both classes of isoforms. (Table 1.2.) 
Indeed, the isoforms involved in each pathology produce specific electrophoretic 
profiles according to the number of repeated regions, and can be distinguished based 
on their molecular weight. Figure 1.2. shows the electrophoretic profiles of the three 





Figure 1.2. Electrophoretic profiles of pathological tau proteins with schematic representation 





Table 1.2 Neuropathological features of the tauopathies 
 
 
1.1.2.1. 3R tauopathies  
 
Pick’s disease is the only member of the class of 3R tauopathies, first described by 
Arnold Pick in 1892 [24]. It is characterised by significant neuronal loss, gliosis and 
formation of round, intraneuronal inclusions called Pick bodies [24] that deposit in the 
hippocampus, frontal and temporal cortices [25], as well as to a lesser extent in 
astrocytes and glia [26]. These inclusions are made exclusively of 3R tau assembled 
both into straight filaments of 15-18 nm in diameter and into twisted ribbons 20-22 nm 
wide [27, 28]. Pick bodies are negative with the Gallyas silver stain, which instead 
labels neurofibrillary tangles in AD, but can be visualized by conventional Bodian 
staining when intracellular [29], and with methenamine-silver method when located 
outside the cells [30]. Clinical symptoms include changes in social behavior and 
personality and progressive fluent aphasia with breakdowns in the conceptual 
database. Variants of the disease see the prevalence of progressive nonfluent 
aphasia associated with left peri-Sylvian atrophy [31].  
 
1.1.2.2. 4R tauopathies  
 
Tauopathies with inclusions of 4R tau are more commonly observed, and include a 





Progressive supranuclear palsy 
 
PSP is the most common primary tauopathy and was first characterised as a clinical 
entity in 1964 by Steele et al. [32]. It is considered to be a rare disease with a peak 
prevalence in people around 70-74 years [33]. Tau pathology consists mainly of NFTs 
and intracytoplasmic inclusions called coiled bodies, both reactive with Gallyas silver 
stain [34]. Another hallmark of PSP are tufted astrocytes, densely packed tau fibrils 
which form tufts in the proximal processes around astrocytic nuclei [35].  PSP exists 
in a variety of clinical manifestations driven by the different localization of tau 
pathology in brain areas [36]. The classical phenotype for PSP is the so-called 
Richardson’s syndrome, which combines motor (bradykinesia, unsteady gait, falls) 
and cognitive symptoms (bradyphenia, speech disorders, personality changes). Less 
common clinical presentations associate an overall PSP-like phenotype with other 
deficits, such as parkinsonism, progressive gait freezing, speech language, 
predominant cerebellar ataxia and frontotemporal dementia [37]. PSP with 
corticobasal syndrome (PSP-CBS) is a rare pathological condition with partial overlap 
between PSP and another 4R tauopathy, CBD. PSP-CBS is characterised by a 
variable combination of progressive motor symptoms, and can be distinguished from 




CBD was first described by Rebeiz and colleagues [38] in 1968 as a mainly motor 
disturb, with tremors, dystonia, rigidity and slow movements. Indeed, CBD 
manifestation is usually compared with atypical parkinsonism, although cognitive 
decline also occurs in the majority of patients [39, 40]. From a neuropathological point 
of view, CBD-affected brains exhibit neuronal loss and gliosis in the frontoparietal 
cortex as well as in the frontal and superior temporal lobes. The substantia nigra is 
also affected, with moderate to severe damages. Cortical and limbic regions show the 
presence of ballooned neurons positive for phosphorylated neurofilaments [41], while 
pre-tangle structures made of tau protein are observed in the cerebral cortex and 
subcortical regions [42]. On the contrary, NFTs are not common in CBD patients. 
Degenerating oligodendrocytes present abundance of aggregated tau in the form of 
coiled bodies, and in both white and grey matter there is the accumulation of 
argyrophilic threads, tau-positive threadlike structures located in the processes of the 
cells [43]. Clinical presentation of CBD often overlaps with FTD and PSP, as the all 
share key features like the akinetic-rigid syndrome and eye movement abnormalities. 
However, the presence of specific symptoms, such as the supranuclear gaze palsy 






Globular glial tauopathy 
 
GGT is a recently introduced 4R tauopathy with widespread tau-positive globular glial 
inclusions (GGIs) in oligodendroglial and astrocytic cells [13, 44]. Tau pathology 
extends also to neurons in the form of diffuse cytoplasmic globular or small tangle-
like inclusions [45, 46]. Specific localization of tau aggregates allows the classification 
of GGT cases into three main groups. Type I GGT involve mainly frontotemporal 
cortex and GGIs are found in the white matter. In type II, pathology extends 
predominantly to the motor cortex and corticospinal tract. Type III is a combination of 
the first two and see the presence of tau inclusions in all mentioned brain areas [13]. 
Emerging evidence suggest that GGT tau inclusions have a stronger seeding 
competency compared to other tauopathies, and compare them to GCI-type a-
synuclein aggregates observed in MSA [47]. Further investigations are directed to the 
understanding of this peculiar behaviour, i.e. by characterizing any potential 
ultrastructural difference between GGT-tau and other tauopathies.  
 
Argyrophilic grain disease 
  
AGD is a common but still under-recognized neurodegenerative condition [48], that 
affects people from 65 to 100 years of age [49, 50]. The difficulty in correctly 
diagnosing AGD lies in the fact that it is often associated with other neurodegenerative 
syndromes, mainly AD but also PiD, PD, DLB, PSP, CBD, ALS [51-53], and can thus 
be misinterpreted as one of the phenotypical manifestations of more common 
disorders. Moreover, the definition of a precise clinical phenotype is still lacking, as 
major cognitive symptoms are highly variable and very generic. The most common 
sign of AGD is a slow-progressing, mild cognitive impairment [54], along with 
personality changes and neuropsychiatric symptoms in early and mild stages of the 
disease [55, 56]. However, cases have been reported in which AGD presents without 
cognitive deficits [57]. This vast heterogeneity is the reason why an accurate 
diagnosis is possible only after a post-mortem examination. Indeed, AGD is 
characterised by the deposition of small spindle-shaped aggregates (argyrophilic 
grains) in dendritic processes of neurons [58], positive with Gallyas staining, and pre-
tangles in neurons of the limbic system [59]. Along with neurons, also 
oligodendrocytes accumulate tau inclusions in the form of coiled bodies and neuronal 
pretangles [58].  
 




AD is classified as a secondary tauopathy due to the co-presence of amyloid-ß and 
tau pathologies. Amyloid-ß accumulates into insoluble plaques in the extracellular 
space and in the walls of blood vessels, while protein tau forms NFTs inside neurons. 
The two pathologies develop concomitantly and follow each one its own pattern of 
 14 
progression, which is described by Braak and Braak stages [60] (Figure 1.2). In 
contrast to other tauopathies, one of the major clinical hallmarks of AD is a 
progressive dementia, which characterises the whole clinical phase of the disease (8-
10 years). It is now accepted that AD starts well before the appearance of clinical 
symptoms, with a silent, prodromal stage that can last for over two decades [61]. The 
crude incidence of sporadic AD is of 1-3% with no net prevalence of specific 




Figure 1.3. Braak and Braak staging of AD for amyloid ß (A) and tau (B) [63]. (A) Aß deposits 
progressively spread from the neocortex to the entorhinal area and the hippocampus, then reach the 
subcortical structures, the brain stem and the cerebellum. (B) NFTs made of protein tau start forming 
in the entorhinal cortex and then move to the hippocampus and the neocortical areas, opposite to Aß. 
White arrows indicate the direction of the spreading of the pathological aggregates [60, 64]. 
 
The majority of AD cases are sporadic (around 95%), affect people over the age of 
75-80 years and are a result of the inability of the brain to clear Aß peptide [65]. A 
small portion of patients have autosomal dominant inherited AD (DIAD), which is more 
aggressive than its sporadic counterpart and starts to appear at around 45 years of 
age. In more than half of the cases of DIAD, mutations were found in one of three 
different genes: the amyloid precursor protein gene (APP), and the genes for 
presenilin-1 and presenilin-2 (PSEN1 and PSEN2) [66-69]. Most mutations in APP 
gene modify the APP processing and result in an increased production of the 
pathogenic fragment Aß-42 and in a higher ratio Aß-42: Aß-40. The same outcome is 
observed for the mutations affecting the presenilins, which are responsible of APP 
cleavage [70, 71]. For what concerns sporadic AD, potential environmental risk factors 
have been determined, including diabetes mellitus, mid-life hypertension, obesity and 
inactivity, smoking and depression [72]. Their direct association to AD pathology is 
not straightforward, as these lifestyle interventions provide amelioration to the overall 
well-being of people. A key genetic risk factor has been identified and proved certain, 
that is the polymorphism associated with the apolipoprotein E gene (APOE) [73, 74]. 
APOE exists in 3 isoforms that differ for 1 or 2 amino acids. Population studies showed 
that while the allele APOE2 reduces the risk for AD, having the APOE4 allele 
increases the probability of developing AD by three times in heterozygosity and twelve 
times in homozygosity [75]. Studies have shown that APOE acts only on Aß, by acting 
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as a chaperone and affecting its clearance and degradation, while it has no effect on 
tau hyperphosphorylation [76, 77]. 
Unlike other tauopathies, AD is characterised by the presence of all six isoforms of 
tau in the insoluble sarkosyl-extracts, forming the characteristic triplet of 60, 64 and 
69 kDa, with additional minor bands at 72/74 kDa. This profile classifies AD as a 
3R/4R, or “mixed” tauopathy. Tau aggregation seems to be initiated by the abnormal 
hyperphosphorylation of specific amino acidic residues [78, 79], which alters the 
protein’s overall charge and causes its detachment from the microtubules. The 
increase in the amount of soluble cytoplasmic tau is the first step in the aggregation 
cascade. Tau aggregates mainly in the form of NFTs, but a small portion of other 
structures called straight filaments (SFs) is present [80-82]. NFTs are often called also 
paired helical filaments (PHFs) because of their appearance as helically wounding 
around each other. In 2017, Fitzpatrick et al. provided the first high-resolution (3.4-3.5 
Å) map of PHFs and SFs structure using cryo-electron microscopy [83]. Despite their 
visible differences, PHFs and SFs share an ordered core of protofilaments spanning 
residues 306-378, with the C- and N- termini forming a fuzzy coat all around. The core 
is composed by structural motifs packed in in register, antiparallel cross-ß/ ß helical 
structures kept together by a mixture of hydrophobic and polar interactions. PHFs and 
SFs differ in their inter-protofilaments packing and are thus considered as structural 
polymorphs.    
Aß is thought to be the trigger, or even the driver, of the whole disease process, at 
least in familial cases. The presence of tau pathology is mandatory for the diagnosis 
of AD, and although the precise interactions between the two proteins have not been 
fully elucidated yet, many theories have been proposed. The amyloid hypothesis 
postulates that tau alterations occur as downstream events of Aß deposition [84-86], 
while it is equally plausible that the two players proceed in parallel and enhance each 
other’s toxicity [87].  
Aß aggregates persist in the brain for many years and their amount increases over 
time, due to the ability of Aß to act as a template and induce aggregation [88]. Later, 
it was showed that the same effect can be obtained by using either brain 
homogenates containing Aß plaques, or synthetic aggregates made of recombinant 
Aß, although with a lower efficiency compared to brain material [89, 90]. This property 
is referred to as “prion-like seeding”, and will be further discussed in a dedicated 
section of this work.  
 
1.1.3. Transmissible Spongiform Encephalopathies  
 
Prions are the causative agent of a panel of distinct neurodegenerative disorders 
called TSEs, which affect both humans and a wide range of animal species. Differently 
from all the other neurodegenerative diseases, prion disorders are the only ones for 




1.1.3.1. Animal TSEs  
 
Animal prion diseases include scrapie of sheep, goats and mouflons [91], bovine 
spongiform encephalopathy (BSE) in cows [92], transmissible mink encephalopathy 
(TME) in ranch-reared minks [93], feline spongiform encephalopathy (FSE) in 
domestic cats [94], chronic wasting disease (CWD) of cervids and spongiform 
encephalopathy of primates [95]. Animal TSEs are generally acquired through direct 
contact with contaminated urine and feces or with carcasses. Scrapie was the first 
animal TSE to be recognized and studied in detail. Neuropathologically, scrapie 
causes spongiform vacuolation in the CNS, astrogliosis and deposition of PrPSc in the 
form of amyloid plaques Affected animals may show signs of aggressive behaviour, 
ataxia and hyperactivity. The same symptoms characterise also BSE, which exists as 
a “classical form” (cBSE), as well as two atypical variants, H-type BSE and L-type 
BSE [96]. Atypical BSEs differ from cBSE in their neuropathological profile, and can 
be transmitted to transgenic mice and primates through intracerebral inoculation [97, 
98]. The most recently discovered TSE is CWD, affecting both captive and free-
ranging animals of the family of Cervidae. Its etiology is still unknown but might be 
linked to scrapie, as white-tailed deer intracerebrally inoculated with the scrapie agent 
developed a disease that closely resembles CWD [99]. TME and FSE are very rare 
disorders, with only a few cases identified.  
 
1.1.3.2. Human TSEs  
 
Human TSEs form a heterogeneous group of disorders with sporadic, genetic or 
acquired etiology, although the majority of cases are idiopathic. Acquired TSEs can 
be contracted from contaminated neurosurgical instruments, corneal transplantation, 
dura mater grafting, brain derivatives like pituitary hormone, and from consumption of 
prion-tainted beef products [100]. The latter is the only reported case of inter-species 
transmission between animals and humans, that developed a pathology with a very 
rapid course defined as variant Creutzfeldt-Jakob disease (vCJD). Nevertheless, 
letting alone this unexpected outbreak, the number of acquired TSEs cases is 
negligible.  
Genetic TSEs account for the 10% of total cases, start to manifest at a younger age 
compared to sporadic disorders and have generally a more aggressive phenotype. 
Genetic forms include familial CJD (fCJD), Gerstmann-Sträussler-Scheinker disease 
(GSS) [67], fatal familial insomnia (FFI) [68] and prion protein cerebral amyloid 
angiopathy (PrP-CAA). More than 40 mutations in the PRNP gene are linked to the 
onset of these diseases, mainly located at the C-terminus of the protein. Among, all, 
the mutation Asp178Asn received particular attention because its pathogenic effects 
are dependent on the allele combination at codon 129. Indeed, if the mutation is 
coupled with the presence of a valine residue at codon 129, there is an increased risk 
of developing fCJD, while if there is a methionine residue, the favoured disease is FFI. 
In general, the M/M homozygosity is linked to an earlier onset and a shorter course of 
genetic prion disorders [101, 102]. 
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sCJD is the most common human prion disorder and accounts for about 85% of 
cases, with an age of onset of 70 years. Symptoms develop rapidly, and affected 
people die within a year from the initial manifestations. sCJD is thought to result from 
somatic mutations of PRNP gene or from random structural changes in the 
conformation of PrPC; according to epidemiologic studies, no environmental factor 
seems to be linked to the pathology. sCJD is characterised by phenotypic 
heterogeneity due to the different PrPSc deposits, linked to the type of polymorphism 
at codon 129. The two types of PrPSc have distinct PK-resistance, aggregation 
properties, transmissibility and form peculiar brain lesions, probably as a 
consequence of specific structural features [103]. 
 
1.1.3.3. Prion diseases with tau pathology  
 
Although the main hallmark of neurodegenerative disorders is the presence of 
aggregates constituted exclusively of one or more specific protein, there is increasing 
evidence that these diseases are not as isolated and separated entities as we may 
think. Work from Perez et al. and Lopes et al. identified in the GSK-3ß and Cdk5-
mediated pathways two points of contact between prion, tau and Aß pathologies [104, 
105]. Prion protein peptides spanning the amyloidogenic region can increase the 
activity of GSK-3ß, which in turn hyperphosphorylates tau [104]; a similar effect is 
achieved when the same peptide, together with Aß 1-40, deregulates the kinase Cdk5 
and cause the hyperphosphorylation of tau at Ser202/Thr205 [105]. 
Reports of the co-presence of prion deposits and tau pathology come mainly from 
inherited prion disorders, which lead to the formation of dystrophic neurites with 
abundant hyperphosphorylated tau specifically in the proximity of large prion plaques. 
Classical cases of GSS with the point mutation P102L were the most affected by 
concomitant tau phosphorylation, but similar findings occurred also in cases of GSS 
with the A117V and P105L mutations. The absence of Aß deposition hints at a PrP-
induced tau phosphorylation, conversely to what is thought to happen in AD. Indeed, 
prion protein peptides carrying the A117V mutation were very effective in displacing 
tau protein and inhibiting microtubules formation, possibly leading to NFTs deposition 
[106]. Following these observations, bot acquired and sporadic cases of CJD were 
examined to further characterise this phenomenon. vCJD patients presented diffused 
tau pathology with a pattern of hyperphosphorylation very similar to AD, but unlike the 
latter, hyperphosphorylation remained limited to tau deposits near amyloid plaques 
and did not apply to soluble tau [107]. Only a few cases of sCJD showed also tau 
pathology, and specifically in association with small prion plaques [108]. The 
hypothesis that only plaque-forming prion disorders might be able to induce tau 
phosphorylation remained valid until a study of a large cohort of sCJD patients 
revealed that also synaptic PrP deposits that do not form plaques trigger tau 
aggregation and phosphorylation. More in detail, the prion protein burden is correlated 
with the presence of tau aggregates in the forms of rods and stubs [109]. While the 
co-deposition of NFTs and prion plaques is considered as a sort of side-effect in 
classical prion disorders, it becomes the major sign of a rare form of prion disorder 
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called PrP-cerebral amyloid angiopathy (PrP-CAA) [110]. This peculiar case of 
dementia arises from a nonsense mutation at codon 145 of PrP, and is characterised 
by extended PrP deposition in the walls of small and medium-size vessels, as well as 
in the surrounding parenchyma. Neurofibrillary tangles and neurophil threads are 
abundant especially in the pyramidal and granule cells of the hippocampus, and are 
closely associated with parenchymal amyloid plaques. However, the relationship 
between prion and tau pathologies remain to be further investigated. 
 
1.1.4. Amyotrophic Lateral Sclerosis (ALS)  
 
ALS is another neurodegenerative disease characterised mainly by motor symptoms 
and resulting in progressive motor weakness due to the degeneration of motor 
neurons in the spinal cord and cerebral cortex [111]. Two misfolded proteins are 
involved in the pathogenesis of ALS: superoxide dismutase 1 (SOD1) and TAR DNA-
binding protein 43 (TDP-43). Mutations in SOD1 are the principal cause of familial 
forms of ALS, which account for around 10% of cases. More than 180 point mutations 
of SOD1 have been identified [112, 113], and their general effect is to lead to structural 
instability of the mutant, with subsequent misfolding and aggregation. The same 
occurs if wild-type SOD1 undergoes oxidation or post-translation modification that 
alter its structure. In cell-free systems, the incubation of wild-type SOD1 with its 
mutated counterpart alone caused aggregation of the wild-type form, pointing at the 
hypothesis of ALS as a prion-like disorder. 
TDP-43 inclusions have been found in the majority of sporadic cases of ALS and in 
around 50% of cases of frontotemporal dementia [12]. In addition, TDP-43 has been 
found in association with other proteins in Huntington’s disease and, to a minor extent, 
in AD. Indeed, TDP-43 is a very important regulatory protein that binds to pre-mRNA 
molecules and affects the splicing and the expression level of more than 500 mRNAs 
[114]. Usually TDP-43 is located in the nucleus, but in pathological condition 
translocate into the cytoplasm, becomes hyperphosphorylated and starts 
aggregating. Growing evidence shows that TDP-43 possesses a prion like behaviour; 
aggregates isolated from ALS patients were able to recruit and misfold the 
endogenous protein in human neuroblastoma cells, resulting in amyloid structures 
with strong similarities to what observed in vivo, including ubiquitination and 
hyperphosphorylation. To exclude any contribution from non-specified brain material, 
synthetic TDP-43 seeds were used to template the aggregation of the endogenous 
protein in human embryonic kidney cells, leading to similar results [115]. Taken 









1.2. Proteins involved in neurodegenerative disorders 
 
1.2.1 Tau protein  
 
Tau proteins are members of the microtubule-associated proteins (MAP) family. In 
humans, they are found mainly in neurons [116], with trace amounts in peripheral 
tissues [117] and in non-neuronal cells, especially in pathological conditions [118].  
Although people commonly refer to tau as a single protein, they are actually a small 
family of six isoforms, originating from the alternative splicing of the MAPT gene 
located on chromosome 17q21 [117] in humans.  Given this clarification, from now on 
the common way of referring to tau as a single entity will be adopted wherever it is 
not necessary to discriminate.  
 
1.2.1.1. Tau structure  
 
MAPT gene has 16 exons, but only some of them are constitutively translated [23] 
(Figure 1.3). Exons 2, 3 and 10 are alternatively spliced in the adult brain, giving rise 
to the different isoforms, that range from 37 to 46 kDa [119]. MAPT exons 2 and 3 
encode each for a N-terminal insertion of 29 amino acids, and exon 3 is never present 
without exon 2. Exon 10 encodes the second (R2) out of four highly conserved 
imperfect repeated regions of 31 amino acids, which constitute the microtubule-
binding domain of tau proteins, the other being encoded by exons 9, 11, 12. Taken 
together, these splicing variations yield six tau isoforms that differ for the presence of 
zero, one or two N-terminal insertions (0N, 1N, 2N) and the presence of either 3 or 4 
imperfect repeats (3R and 4R) in the C-terminal part of the protein. Tau proteins 
expression is developmentally regulated, with fetal brain expressing only 0N3R tau 
(also called “fetal tau”), while in adult CNS all isoforms are present, although at 
different levels [79]. The ratio between 3R- and 4R- tau isoforms is around 1:1 in 
healthy brains. Maintaining this equilibrium is crucial to avoid the onset of pathological 
situations, as many tau-related disorders show the prevalence of one class of 
isoforms over the other [120].   
 
 
Figure 1.4. Structure of MAPT gene and of the different isoforms resulting from alternative 
splicing [121].  
 
 20 
  1.2.1.2. Tau functions  
 
Tau protein functions are strictly related to its structure. Like a-synuclein, tau is a 
hydrophilic protein which maintains a highly flexible and unfolded conformation in 
solution [122]. The N-terminal part has a high content of acidic residues in the two 
additional insertions, followed by a proline-rich region. This segment is called the 
projection domain, as it projects from the microtubule surface and interacts  with 
cytoskeletal components [123] and cytosolic organelles [124]. Moreover, the length of 
the projection domain is crucial in determining the axonal diameter, as it regulates the 
spacing between microtubules [125]. Indeed, peripheral neurons with very long and 
large axons usually express a longer tau isoform, called “big tau”, which includes an 
additional N-terminal sequence encoded by the exon 4A [126].   
Tau mediates also the interconnections between microtubules and neurofilaments 
[123] through the binding with spectrin [127] and actin [128], interacts with 
mitochondria [124] and with the neural plasma membrane.  
The central proline-rich sequence is involved in interactions with receptor proteins, 
mediating many important roles in signal transduction pathways. The binding site 
PXXP for the SH3 domain of src-family non-receptor tyrosine kinases, such as fyn, is 
located in the sequence of tau spanning residues 231-237, and the two proteins were 
shown to colocalize beneath the plasma membrane, suggesting a role for tau in the 
signaling cascade modifying the cell shape [129]. A similar interaction occurs with the 
SH3 domain of phospholipase-C gamma isozymes [130]. 
The repeated regions R1-R4 located in the C-terminal part of the protein are involved 
in the binding of tau to the microtubules network, along with the less-conserved inter-
repeat regions. In particular, they regulate tau ability to promote polymerization of 
tubulin into mature microtubules, inhibit the rate of depolymerization [131], and are 
involved in axonal transport [128, 132] [127]. The binding to microtubules is mediated 
by the 18-amino acid repeats through an array of weak sites. 4R isoforms are more 
efficient in interacting with microtubules than 3R isoforms thanks to the presence of 
the inter-repeat R1-R2 (peptide 274KVQIINKK281), which increases the strength of the 
binding by 40 times [133, 134].  
Recent data proposed that tau protein might also bind RNA through tis microtubule-
binding domain [135]. Indeed, tau has been found also in the nucleus [136], and its 
lower solubility indicates that nuclear tau undergoes different post-translational 
modifications, like phosphorylation at specific sites [137]. Once in the nucleus, tau 
might play a role in developmental pathways, for example by binding the homeotic 
repressor proteins Eed.   
 
 1.2.1.3. Post-translational modifications of tau protein 
 
Tau protein undergoes a number of post-translational modifications, including 
ubiquitination, glycation, acetylation, nitration and phosphorylation. As dysregulation 
of tau homeostasis and physiology is always a central event in tau-related 
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pathologies, it is of crucial importance to understand the modes of tau regulation 




Phosphorylation is the most common post-translational modification of tau protein. 
More than 80 phosphorylation sites have been identified along the amino acidic 
sequence (Figure 1.4) [23], suggesting that this modification has deep impacts on tau 
physiological functions. The addition of phosphate groups on specific residues of tau 
is essential to modulate its binding affinity for the microtubules [138]: higher the 
number of phosphate groups, lower the ability to interact with tubulin. In particular, 
phosphorylation at S262, S293, S324 and S356, which are located in the KXGS 
repeats of R1, R2, R3 and R4 domains, is known to decrease tau binding to the 




Figure 1.5. Phosphorylation pattern on human full-length tau protein in both normal and 
diseased brains [140]. Phosphorylation sites are indicated with different colors according to their 
physiological (blue) or pathological nature (red). Some sites are phosphorylated both in normal and AD 
brains (green), while other sites have not been fully characterised yet (black). While phosphorylation is 
almost equally distributed along the protein in healthy brains, AD-associated sites are concentrated in 
the microtubule-binding domain and in the C-terminal part. In purple are listed the antibodies that 
recognize specific phosphorylated epitopes.  
 
Tau hyperphosphorylation on the proline-rich region [141] and the C-terminus [142] 
induce self-aggregation of the cytosolic protein, which forms first oligomeric species 
and then insoluble fibrils. Several lines of research indicate that abnormal tau 
phosphorylation might promote neurodegeneration also by compromising axonal 
integrity and synaptic functions [143], and by protecting it from degradation by the 
proteasome system [139]. Multiple kinases and phosphatases take part in the 
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regulation of tau phosphorylation, often with more than one protein taking care of a 
single phosphorylation site [144-146]. Three classes of kinases phosphorylate tau 
(PDPK kinases, non-PDPK kinases and kinases specific for tyrosines), while more 
than 70% of the dephosphorylation activity is carried out by PP2A alone. Alterations 
in the levels of GSK3ß have been reported in patients with AD [147-149], along with 
reduced activity of PP2A [150, 151]; inhibition of GSK3ß in transgenic mice reduced 
neurodegeneration, blocked NFTs formation and rescued neuronal loss, pointing at 
this kinase as a promising therapeutic target [152-154]. In 2018, Gandini et al. 
developed a multitarget directed ligand that simultaneously inhibits GSK3ß and the 
tau aggregation process, therefore triggering a synergistic response and eliminating 




Glycans can be added to proteins on the amine group of Asn (N-glycosylation) or on 
the hydroxylic group of Ser and Thr (O-glycosylation). Tau protein from AD brains was 
found to be abnormally glycosylated, and in some cases also completely devoid of 
sugars [155, 156]. Indeed, O-glycosylation with the addition of N-acetyl glucosamine 
seems to compete with phosphorylation operated by GSK3ß, PKA and CDK5 on 
specific sites such as S356 [157, 158]. This is suggested also by the fact that impaired 
glucose metabolism plays a role in the onset of AD, promoting NFTs formation 
through reduction of O-glycosylation and GSK3ß over-activation [159]. Moreover, in 
vitro deglycosylation of tau aggregates disrupts the amyloid-like structure and 
restores tau ability to interact with microtubules [156]. These observations all suggest 




Tau undergoes truncation at D13, E391 and D421 in AD, and this modification is 
correlated with disease progression [160, 161]. Truncation is mediated by caspase 3 
at position D421, while calpains might cut either at positions 45 or 231, generating a 
17 kDa fragment [162]. Truncated forms of tau are enriched in PHFs and totally absent 
in control brains, which is consistent with their role in promoting aggregation and 
apoptosis [163]. It is now widely accepted that truncation occurs after pathological 
hyperphosphorylation of tau, but before the formation of NFTs [164-166].   
Phosphorylation at S422 protects tau from caspase-mediated cleavage at D421, 





Nitration consist in the addition of nitrogen dioxyide to Tyr residues of proteins. Tau 
nitration occurs on 4 sites and involves both soluble tau and PHF-tau [168, 169], but 
its role in aggregation is not yet clear. Nitration at site Y18 is not related to pathology, 
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as is found both in AD and control brains [170], whereas nitration at Y197 and Y394 
lead to in vitro tau polymerization but not aggregation [171].  
 
Ubiquitination and SUMOlation 
 
As the majority of proteins, tau is ubiquitinated on residues K254, K311 and K353 in 
order to be degraded by the UPS[172, 173]. Increasing tau ubiquitination leads to a 
reduction of tau lesions in transgenic mice overexpressing tau [174], but its role in the 
pathology is only secondary. Tau can also be SUMOlated at K340 by SUMO1, 
SUMO2 and SUMO3 [175]. SUMO1 colocalizes with tau aggregates only in APP 
transgenic mice, suggesting that Aß pathology is required for tau SUMOlation [176].  
 
1.2.1.4. Truncated constructs of tau  
 
All the six isoforms of tau show propensity to in vitro aggregation, although to a 
different extent according to their amino acidic composition. As a general rule, it has 
been observed that 4R tau isoforms aggregate more readily than their 3R 
counterparts, and this is due to the presence of the extra repeated region R2 in the 
microtubule-binding domain. Indeed, structural studies of tau filaments REF revealed 
that the core of the aggregates is composed by the repeated regions, while the rest 
of the protein forms a fuzzy coat all around it. Specifically, solid state NMR showed 
that only some residues (from 306 to 324) formed actual b-sheets [177], while the rest 
of the microtubule-binding domain remained relatively dynamic and the N- and C-
termini (amino acids 1-212, 399-441) were highly mobile[178]. As full-length forms of 
tau have low tendency to in vitro polymerization, two truncated constructs have been 
developed that include only the repeated regions, either in its 4R version (K18) and 




Fig 1.6. Schematic representation of the two subclasses of human tau isoforms (4R and 3R) 
and of the truncated fragments K18 and K19 [179]. The two constructs are often used as model 
systems to mimick the properties of the respective subclass of isoforms.  
 
K18 and K19 aggregate much faster and in a reproducible way in the presence of 
anionic cofactors (RNA, arachidonic acid, heparin), that are needed to screen the 
basic charges of lysine residues. Since their first characterisation in 1994 [180], K18 
and K19 fragments have been widely used to produce synthetic amyloids for cell 
 24 
culture and in vivo studies, both in their wild-type form or with pathological mutations 
(i.e. P301L). Although these recombinant filaments helped in gaining insights into 
many aspects of tau structure and aggregation, their peculiar amino acidic sequences 
present some limitations that should be taken into consideration. Tau K18 and K19 
represent artificial constructs not represented in nature, and are devoid of any post-
translational modification that might influence their behaviour. Moreover, the use of 
arbitrary cofactor to promote their aggregation could result in substantial differences 
compared to brain-derived amyloids. This latter aspect, as well as the resolved 
structure of pathological tau aggregates from various tauopathies, will be discussed 
in section 1.3.3.1. Therefore, it remains unclear how much of the results obtained 
using these tau fragments is actually biologically relevant.  
 
1.2.2. Prion protein 
 
The cellular prion protein, denoted as PrPC, is a glycosylphosphatidylinositol (GPI)-
anchored protein located on the outside leaflet of the cell membrane of many cell 
types, with the highest concentration in the brain [181-183]. PrPC is encoded by the 
PRNP gene (Prnp in other species) present as a single copy gene on chromosome 
20, and its complete open reading frame (ORF) is located within a single exon [184-
186]. In mouse, sheep, cattle and rat the gene has three exons with the ORF located 
in exon 3, while in humans, Syrian hamster and opossum the gene is composed only 
of two exons, and the ORF is positioned in exon 2. The other exons contain the 
promoter and the terminator sites. It has been shown that the physiological form PrPC 
and the infectious protein component PrPSc share the same amino acidic sequence, 
and their different properties are defined only by the three-dimensional arrangement 
of the residues [187, 188]. 
 
1.2.2.1. Biogenesis and structural features of the cellular prion protein
  
PrPC is transcribed first as a pre-pro-protein of 253 amino acids containing the signal 
sequence (first 22 amino acids) for the targeting to the endoplasmic reticulum (ER). 
Once in the lumen, the signal peptide is cleaved and the resulting immature protein 
undergoes several post-translational modifications including N-linked glycosylation on 
N181 and N197 (numbered according to the human protein), disulphide bond 
formation at positions C179 and C214, and removal of the last 23 amino acids with 
subsequent attachment of the GPI anchor at position 231 [189-191]. The mature form 
of PrPC that is released from the ER has 209 amino acids [192]. In addition to this 
prevalent, mature PrPC that is translocated to the cell surface through the exocytic 
pathway, two other topologically different forms are produced. CtmPrP and NtmPrP have 
both their hydrophobic domain (residues 110-134) inserted in the membrane of the 
ER compartment, and have respectively their C-terminal or N-terminal inside the ER 
lumen [193]. Their roles are not yet fully elucidated, but might be related to 
neurotoxicity and death, especially in the case of inherited prion diseases [194].    
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Once the ER-related processing is completed, mature PrPC is sent to the Golgi 
apparatus, where further modifications of N-glycans to held complex sugar chains 
occur. PrPC can be either non-glycosylated, mono- or diglycosylated on Asn181 and 
Asn197 (on human PrPC) [195]. Glycosylation profiles vary in the different regions of 
the central nervous system, but the specific roles of glycosylation are not yet 
understood.  
Mature PrPC localizes mostly in the cholesterol- and sphingolipid-enriched domains 
of the plasma membrane, also called lipid rafts. This interaction seems to be important 
also for the preservation of the correct folding, as cholesterol depletion leads to 
misfolding [196].  
PrPC is constitutively internalized and recycled back to the cell surface with transit 
times of around 60 minutes [197]. Constitutive endocytosis of PrPC is mediated either 
by “caveolae-like” domains or by chlatrin-coated vesicles [198, 199], which bind to the 
N-terminal positively charged motif KKRPKP. Then, PrPC can be sent to the late 
endosomes and lysosomes for degradation, or routed again to the cell surface for 
further recycling. Other than in lysosomes, PrPC can be degraded through the UPS-
ERAD degradation pathway in the cytosol.  
Bacterially expressed recombinant PrP (recPrP) is structurally equivalent to 
physiological PrPC, and it has been used to gain more structural insights into the 3D 
organization by means of NMR and X-ray crystallography. The full-length form of PrP 
has a peculiar structure, conserved among different species: the N-terminal domain 
(amino acids 23-127) is unstructured in solution, while the C-terminus (amino acids 
128-231) is folded into a globular conformation, with prevalence of alpha-helical 




Figure 1.7. Domain organization (A) and 3D-structure (B) of the human PrPC (23-231) [202]. (A) 
Schematic primary structure of the cellular prion protein showing the division in two domains and the 
positions of the three alpha helices and two ß-sheets. The disulphide bond between Cys179 and 
Cys214 is also indicated. (B) Tertiary structure of the cellular prion protein showing the structurally 
defined C-terminal domain and the unstructured N-terminus, with the octarepeat region in brackets. 
Blue dots represent metal ions that are coordinated by the OR. Both the glycosylation sites and the 
GPI anchor are present.  
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The N-terminus of PrPC can be divided into four sub-domains, a first charge cluster 
(CC1), the octarepeat region (OR), a second charge cluster (CC2) and a hydrophobic 
region containing the conserved motif AGAAAAGA. It is considered to act as a broad 
molecular sensor [203] and interacts with copper ions, sulphated glycosaminoglycans 
and the neural cell adhesion molecule (NCAM). Moreover, the N1 fragment (amino 
acids 23- 110/111) generated from the alpha cleavage of PrPC by ADAM proteases 
is involved in the binding with Aß oligomers which triggers the signalling cascade 
mediating the toxic effects of these species [204]. A similar interaction occurs also 
with α -synuclein fibrils, although the exact region has not been identified yet [205]. 
The globular domain of PrPC is composed of three α-helices (α1, α2, α3) and two 
short ß-strands that form an antiparallel ß-sheet. A third ß-strand was recently 
identified and named ß0 [206, 207]. The α-helical regions have been shown to 
undergo a vast structural rearrangement into ß-sheets when PrPC-PrPSc conversion 
occurs. Helices α2 and α3 constitute the core of the globular domain and are kept 
close by the disulphide bond between Cys179 and Cys214. Any disruption of this 
covalent link between the helices might be responsible for the structural modification 
that lead to prion formation. 
 
1.2.2.2. Prion protein functions 
 
The prion protein is expressed in many organs and tissues, but prevalently in neurons 
of the central nervous system, suggesting that it plays key roles in the brain. However, 
data regarding the physiological function of PrPC are still controversial and do not offer 
a sufficiently clear and detailed overview on this protein.  
Given that PrPC is a highly conserved protein among mammals, it was expected that 
the generation of Prnp-ablated mice would have shed light on the still unknown 
functions of the protein. Nonetheless, the first two lines of PrP-null mice (Zurich and 
Edinburgh mice) did not show any significant phenotype, with no abnormalities in the 
brain or in peripheral tissues. These observations indicated that either PrPC was not 
mandatory for normal development, or that other proteins were able to compensate 
for its absence [208, 209]. In contrast to these two lines, in which the knocking-out 
had been achieved simply by interrupting the ORF of Prnp gene with insertion 
cassettes, new mouse lines from which the Prnp gene had been completely deleted 
showed signs of ataxia and degeneration of Purkinje cells [210, 211]. The phenotype 
was rescued with the introduction of functional PrPC. Later, it was discovered that this 
phenotype was due to the overexpression of the PrP paralog gene Doppel (Dpl), 
whose expression is overactivated by the deletion of a splice acceptor site in exon 3 
of Prnp gene. To overcome the drawbacks of the deletion approach, Schmitt-ULM’s 
group described the generation of PrP-knockout cell lines using the CRISPR/Cas9 
approach [212]. With this innovative technology, PrP expression was ablated in N2a 
neuroblastoma cells, C2C12 myoblasts and NMuMG epithelial cells, revealing many 
potential roles of the prion protein: cellular adhesion and differentiation, receptor 
activity, signal transduction, metal binding, neuritogenesis. 
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Role of PrPC in neuritogenesis  
 
Inside the cells, PrPC concentrates at the synaptic level. The accumulation of PrPC in 
the synaptic terminals is in line with experiments that proved that the protein induces 
rapid increases of axons and dendrites [213]. In addition, the expression of PrPC on 
the surface of growth cones is essential for their growth and neurite formation [214]. 
Indeed, soluble forms of PrPC secreted from the membrane and released in the 
extracellular space behave as signalling molecules to trigger neuritogenesis, and GPI-
anchored PrPC on recipient cells acts as its receptor. The growth effect promoted by 
recPrP was completely abolished when either the N-terminal or the C-terminal 
domains were blocked with antibodies, indicating that this function is dependent on 
the interplay between the flexible N-terminal domain and the C-terminus. Specifically, 
the binding of copper ions is essential to maintain the neuritogenic function, and the 
elimination of the copper-binding residues resulted in neuronal toxicity [215]. 
Neurite outgrowth is mediated also by the NCAM-fyn signalling cascade. PrPC and 
NCAM were found to co-localize in lipid rafts of neurites and growth cones [216]. PrPC 
accumulates in lipid rafts enriched in p59fyn non-receptor tyrosine kinase (fyn), which 
in turn is activated by the binding between NCAM and RPTPα. Clustering of NCAM 
results in its redistribution inside lipid rafts [217], where it can interact with PrPC, be 
stabilized and promote neurite outgrowth.  
 
PrPC function in myelin homeostasis 
 
The cellular prion protein is involved in maintaining the myelin homeostasis of 
peripheral neurons, and the ablation of its expression leads to a chronic demyelinating 
polyneuropathy affecting primarily Schwann cells. The receptor on Schwann cells that 
mediates PrPC activity in myelin maintenance was identified as the G protein-coupled 
receptor Gpr126, which interacts with the flexible tail of PrPC and triggers a cAMP 
response resulting in improved myelination[218]. Specifically, the polycationic 
sequence of PrPC (KKRPKPG) is very similar to the motif of the Gpr126 agonist type-
IV collagen, suggesting that the prion protein might act as an agonist of the GPCR 
receptor.   
 
Modulation of NMDA receptors by PrPC 
 
N-methyl-D-asparthate (NMDA) receptors are a subclass of ionotropic glutamate 
receptors whose activation contributes to the excitatory post synaptic potential 
(EPSP) and long-term potentiation (LTP) [219]. The overactivation of NMDA receptors 
leads to an increased influx of Ca2+ that can greatly damage the cells. This 
phenomenon, called excitotoxicity, is involved in many neurodegenerative diseases, 
including AD [220].  Studies on PrP-null mice revealed that in the absence of PrPC, 
the activity of NMDA receptors is enhanced, and postsynaptic currents have longer 
decay times and larger amplitude than in wild-type mice [221]. When PrPC is 
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expressed, excitotoxicity is repressed through a mechanism that requires copper 
[222]. Specifically, copper ions bound to PrPC facilitate the S-nitrosylation of the 
cysteine residues of NMDA receptors, with the consequent inhibition of their activity 
and a reduction of the neurotoxic effects. An interference with copper binding to PrPC 
might underlie the detrimental effects of Ab, which causes neuronal cell death by 
interacting with PrPC and altering the normal activity of NMDA receptors [223]. 
 
 
1.2.2.3. PrPC- PrPSc conversion  
 
As mentioned before, the physiological form PrPC and its pathological counterpart 
PrPSc share the same amino acidic sequence. The acquisition of peculiar properties 
(resistance to proteases, infectivity, insolubility) by PrPSc is essentially a result of the 
different 3D arrangement of the amino acids that alters the equilibrium between 
secondary structure elements by increasing the number of ß-sheets of around 40%. 
First hints of the idea of PrP as a “double-faced” protein came from the observation 
that PrP-null mice were not susceptible to PrPSc infection and transmission, which 
meant that the expression of PrPC was an absolute requirement for the development 
of TSEs [208]. Evidence of the infectious transmissibility of scrapie to goats led first 
to the speculation [224] and then to the experimental demonstration [225, 226] that a 
protein alone could be the infectious moiety responsible for the onset and 
transmission of a disease. Indeed, the term “prion” coined by Prusiner is the short for 
“PRoteinaceous Infectious ONly particle” and refers to the unique properties of this 
unusual infectious agent.  
The “protein-only hypothesis” proposes that the central event in prion diseases onset 
and progression is the self-propagating conversion of PrPC to PrPSc. The in vitro 
generation of infectious prions starting only from synthetic proteins [227-230], in the 
absence of genetic material, corroborated this hypothesis that is now widely accepted.  
From a molecular point of view, PrPSc is thought to first recruit the monomeric PrPC 
through direct interaction, then act as a template to imprint its own aberrant 
conformation and finally incorporate the newly formed PrPSc moiety into the growing 
polymers that in the end will result into insoluble plaques depositing in the CNS. The 
accumulation of PrPSc increases exponentially over time, as big aggregates are 
broken into smaller pieces which behave each one as independent seeds [231].   
Two mechanisms have been proposed for the autocatalytic conversion of PrPC into 
PrPSc. The nucleation-polymerization model postulates that PrPC and PrPSc both exist 
in the cell at an equilibrium that is greatly shifted towards the cellular form, which is 
more stable. Only when an oligomeric nucleus manages to form, PrPSc is stabilized 
and the equilibrium moves towards the scrapie form, allowing the conversion to take 
place. The lag phase observed is explained by the necessity to form the stable 
nucleus. Addition of exogenous PrPSc seeds overcomes the rate-limiting step and 
greatly accelerates the polymerization. The nucleation-polymerization model might 
describe well the initial formation of PrPSc polymers, while the template-assisted 
model might explain the mechanism of fibrils elongation.  
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PrPSc as infectious entity has an oligomeric nature [232], and there is no experimental 
evidence indicating the existence of a stable monomeric unit [201]. Due to its 
insolubility in non-denaturing detergents, the structure of PrPSc has been only 
approximately determined. The use of many biochemical and biophysical techniques 
(spectroscopy, EM, X-rays fiber diffraction, surface reactivity measurements) along 
with molecular dynamics simulations allowed the development of several 3D 
structural models. The ß-helical model originates from EM data on brain-purified 
PrPSc, and proposes that PrPSc is enriched in ß-sheet elements that are arranged to 
form left-handed ß-helices [233] (four rung model). The ß-spiral model derives from 
molecular dynamic simulations of PrP in amyloidogenic conditions. In this case, while 
all the α-helices are retained, the number of ß-strands increases to four and they form 
a spiralling structure that might involve also the unfolded N-terminus. However, this 
model does not consider any cross- ß structure, which are a known characteristic of 
fibrillar PrPSc. Recently, cryo-EM measurements on pure preparations of prions from 
mouse brains showed that PrPSc amyloid fibrils are arranged in a four-rung ß-solenoid 
architecture [234], which fits very well some known structural restraints and 
biochemical characteristics like the high content of ß-sheets and the resistance to 
protease digestion [235]. Indeed, PrPSc is only partially hydrolysed by the proteases 
(i.e. proteinase K) to form a small, C-terminal resistant fragment of approximately 142 
amino acids, called PrPres or PrP 27-30 due to its electrophoretic mobility in SDS-
PAGE gels. PK-resistant PrPSc accumulates in the brain with a pattern that is clearly 
distinct from that of PrPC [236]. More than the fibrils, oligomeric species are thought 
to be the true responsible of prion toxicity. It has been even hypothesized that the 
formation of long fibrils might be a sort of protective mechanism aiming at neutralizing 
the more toxic effect of small aggregates [237]. A similar behaviour has been 
proposed also for the other proteins that are collectively called “prion-like proteins”.  
 
1.3. Prion-like behaviour of tau protein  
 
Prions uncovered a completely new way of disease propagation in which stable 
spreading of distinct misfolded protein conformers occurs between neighbouring cells 
and through anatomic connections. Many other neurodegenerative diseases, 
including tauopathies, exhibit characteristics that are reminiscent of prion disorders, 
as phenotypic diversity and spreading pathology. However, in order for tauopathies 
to be defined ad prion-like disorders, they must meet precise requirements, 
specifically the evidence of cellular uptake, template seeding and intercellular transfer 
of the newly formed aggregates to prompt the aggregation of the endogenous protein 
in recipient cells (Figure 1.8). This hypothesis is now supported by strong evidence 
coming from cell and animal models of tauopathies. Since the majority of the 
experiments were first performed in vitro and then repeated and confirmed in vivo, 
they will be listed according to the prion-like feature they aim to demonstrate: the 
uptake of exogenous fibrils, the induction of aggregation, the formation of distinct 





Figure 1.8. Schematic representation of the prion-like templated misfolding of the endogenous 
protein triggered by the addition of pathological seeds [238]. Prion-like proteins exist mainly in 
their physiological form (green triangles), and even if some misfolded aggregates might be present, 
the equilibrium is strongly shifted towards the native protein. However, when brain-derived or synthetic 
seeds (red squares) are added, they shift the equilibrium towards the formation of aggregates, which 
grow by misfolding native monomers (green squares) and incorporating them in the nascent amyloid. 
Big aggregates are fragmented into smaller pieces so that the number of forming amyloids grows 
exponentially. The resulting products are filamentous aggregates that deposit in the brain. 
 
1.3.1. Cellular uptake of tau aggregates   
 
In order to template the misfolding of the endogenous protein and propagate, tau 
seeds must first enter the cells. Figure 1.9. gives an overview of the identified 
mechanisms mediating tau fibrils internalization.  
Murine neural precursor cells C17.2 readily internalize tau fibrils by macropinocytosis 
mediated by heparan sulfate proteoglycans (HSPGs) [239]. Indeed, aggregates 
formed only by the microtubule binding domain of tau protein (RD-tau, equivalent to 
K18 tau fragment) were found to co-localize with filamentous actin, that is required to 
form the lamellipodia-like membrane protrusions typical of macropinosomes. 
Inhibition of macropinocytosis with various chemicals strongly diminished tau uptake, 
and the same happens when HSPGs are blocked, suggesting that a direct binding 
between these two partners takes place. In vivo, mice treated with a heparin mimetic 
that blocks the HSPGs binding internalized significantly less full-length tau fibrils than 
control mice, meaning that this mechanism is not limited to the uptake of tau 
fragments and thus could be actually involved in the propagation of the disease. 
Smaller, low-molecular aggregated species of RD-tau (identified as dimers and 
trimers), but not long fibrils or monomers, exploit also bulk endocytosis to get to the 
cell cytoplasm of both C17.2 cells and primary neurons [240, 241]. The internalized 
aggregates co-localize with dextran, a marker of fluid-phase endocytosis, and with 
the endolysosomal compartment. Once inside the cells, tau amyloids can be 
transported both anterogradely and retrogradely [241].  
The ability of extracellular monomeric tau to enter neurons was recently questioned 
by Evans et al. [242], who found that both monomeric and aggregated tau easily enter 
stem cells-derived neurons by overlapping but distinct mechanisms both related to 
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regulated endocytosis. Monomeric full-length wild-type and P301S tau are 
internalized first by rapid dynamin-dependent endocytosis and then by a slower, actin-
dependent mechanism consistent with bulk endocytosis. Conversely to what had 
been observed previously [239], perturbation of actin polymerization had little effect 
on the number of aggregates taken up by these neurons, while dynamin inhibitors 
greatly reduced tau aggregates entry with a stronger effect than on monomeric tau. 
These findings are consistent with a classical endocytic mechanism for tau amyloids. 
The discrepancy of their data with previous reports is addressed by the authors as 
related to the type of cells, claiming that human neurons might internalize fibrils via 
different mechanisms compared to the murine primary neurons and non-neuronal 
cells used by Holmes. The question of which molecules mediate the endocytic 
processes is still open, as no receptors or carriers except for HSPGs have been 




Figure 1.9. Potential mechanisms mediating the uptake of tau aggregates between cells 
(modified from [243]). Tau fibrils can be transferred from donor cells (green) to recipient cells (orange) 
through many pathways. Blue and purple arrows indicate pathways experimentally proved; red arrows 
indicate hypothesized mechanisms. Tau aggregates can be transferred through extracellular vesicles 
like ectosomes (A) or exosomes (B) that fuse with the plasma membrane and release their content in 
the cytoplasm. Free and aggregated tau released from donor cells in the extracellular space can bind 
to specific membrane proteins and be internalized by receptor-mediated endocytosis (C) or 
macropinocytosis (D). Monomeric tau is also able to escape from the vesicles and cross the plasma 
membrane simply by diffusion (E). Both tau monomers and aggregates were found inside tunnelling 





1.3.2. Induction of aggregation  
 
Tau aggregation propensity and induced seeding have been extensively studied and 
characterised in cell and animal models. It is believed that tau aggregation in 
pathological situations is initiated by hyperphosphorylation, followed by detachment 
from the microtubules and formation of a compact structure called “Alz50 state”[244]. 
From this point on, tau begins to aggregate into mature fibrils and undergoes several 
truncations. To reconstruct the steps leading to the generation of NFTs, several trials 
were done to reconstitute tau assembly in vitro. Aggregation of soluble tau as a 
consequence of its overexpression was observed by Thioflavin S (ThS) staining both 
in bacterial systems [245] and in neuro2a cells expressing tau under the control of an 
inducible promoter [246]. TauRD has been employed as substrate, and it is still one 
of the most common models in the field of tau aggregation. An in vitro study went 
deeper into this issue, identifying aggregates composed at least of three protein 
monomers as the minimal propagation unit necessary for internalization and induction 
of seeding in HEK293 cell line[247]. Specifically, the aggregation-competent portion 
of tau protein must include the microtubule binding domains, as the formation of fibrils 
is strictly dependent on the presence of at least one of the two hexapeptide motifs 
PHF6 and PHF6*, located respectively at the beginning of the third (R3) and of the 
second (R2) repeated regions [248]. 
Exogenous tau seeds to template the aggregation of the intracellular protein derive 
from brain homogenates of tauopathy patients, transgenic mice showing pathology, 
lysates and conditioned media from transfected cells bearing tau amyloids, and from 
synthetic fibrils generated in vitro. Formation of aggregates was monitored with an 
array of techniques including FRET-based aggregation sensor cells [179], 
fluorescence assays [249], biochemical insolubility assays [250] and 
immunohistochemical detection of pathological inclusions [251-253].  
As it is expectable, tau seeds purified from patients’ brains display a higher seeding 
activity compared to fibrils generated in vitro. Nevertheless, incubation of wild-type or 
P301L-tau expressing cells with small amounts of synthetic preformed fibrils resulted 
in a consistent production of insoluble aggregates that resembled NFTs and exhibited 
a high degree of phosphorylation [254]. The effect of mutated tau was more 
pronounced, consistently with the highly aggressive phenotype of the FTDP-17 
syndrome related to this mutation. Nonaka et al. [255] speculated that a cross-seeding 
barrier exists between 3R and 4R tau, since they observed the formation of 
aggregates only when 3R- and 4R- expressing cells were treated with seeds 
belonging to the same subclass of isoforms. Kinetic analysis of K18 and K19 
aggregation revealed that this barrier is asymmetric, with K19 being able to seed both 
3R and 4R tau while K18 seeds only 4R tau. The explanation is mainly structural; the 
repeat R3 is the preferred site for the binding between the monomeric protein and the 
growing fibril, but when R2 is also present, the interaction with the monomer is 
hampered if the monomer itself does not have R2, while is favoured if another R2 is 
present. When the fibrils are made only of 3R tau and R2 is not represented, the 
interaction can occur with both 3R and 4R isoforms indiscriminately. The presence of 
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R2 makes the whole structure more disordered than 3R tau, reducing the extension 
of the structural core and thus impairing the interaction with different isoforms[256]. 
However, Margittai’s group claimed that the existence of such barrier is nothing more 
than an artefact due to the use of K18 fragment as seed. Indeed, recombinant fibrils 
made of the longest human tau isoform (huTau40) could easily recruit 3R tau 
substrate in in vitro aggregation assays, while K18 aggregates could not[257]. 
Assuming that the presence of ordered regions in the fibrils are required for the 
interaction with monomers, the difference in the seeding activity between K18 and 
huTau40 could be due to the fact that the last region of R4 segment is highly 
disordered in the former and well organized in the latter thanks to the longer amino 
acidic sequence. The reduce contact surface of K18 might explain why 3R monomers 
are not able to bind, whereas the presence of both the N- and the C- termini of the 
protein makes full-length forms of tau better templates for misfolding [257].  
To be sure that this is the way tau pathology proceeds in human brains, many 
researchers took up the challenge to study the behaviour of brain-derived tau 
amyloids when injected into cultured cells and mice. Inoculation of brain homogenates 
from patients with various tauopathies into transgenic mice expressing the longest 
human tau isoform led to the formation of de novo inclusions that recapitulated the 
basic features of the initial pathology and that could be faithfully propagated to the 
next generations[252]. Previously, the same group had already shown that brain 
extracts from P301S expressing mice were capable of inducing the assembly of wild 
type tau in wild-type expressing mice, with subsequent spreading of the pathology to 
the neighbouring regions[251]. Over time, the pathology moves further and further, 
consistently with neuroanatomical transport and induction of pathology along these 
routes. A number of mouse models were created in which tau transgene expression 
was restricted to the entorhinal cortex, in order to follow brain propagation[258, 
259].These studied support the hypothesis of a trans-synaptic movement of tau 
amyloids, as human tau was found in brain areas near the entorhinal cortex where 
the transgene was not expressed (i.e. dentate gyrus, CA fields of the hippocampus, 
cingulate cortex) [258]. The appearance of pathological tau species in brain areas 
around the injection site is often accompanied by the selective loss of neurons in those 
regions. The reliability of such systems has been questioned after the observation 
that the expression of transgenes under the control of the EC-specific promoter for 
neuropsin was not really limited to that region, but could be found in other cortical 
regions[260]. However, the general pattern of spreading was clear enough to 
convince that tau pathology proceeds through trans-synaptic spreading between 
cells.  
Not all tau seeds seem to be able to induce pathology in transgenic mouse models; 
while showing a robust seeding activity in vitro, K18 seeds injected in the 
hippocampus caused only limited aggregation of tau, and peripheral injection did not 
lead to any pathology in the CNS of human-P301L tau expressing mice [261].  
On the contrary, brain extracts from tauopathy patients could trigger pathology also in 
wild-type non-transgenic mice, promoting the aggregation of the endogenous murine 
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protein[252, 262]. This very strong seeding activity firmly supports the prion-like 
behaviour of tau amyloids in tauopathies.  
 
1.3.3. Tau strains 
 
Many of the studies listed above also proved that seeded tau aggregation is 
templated, meaning that the aggregates formed retain the same conformation and 
biochemical characteristics of the original seeds. Different conformers that can be 
faithfully propagates over time are called strains, and are thought to be responsible 
for the phenotypic variability of tauopathies, as is the case for prion disorders. It is 
straightforward to think that the morphology of tau assemblies could be an important 
determinant in defining the type of disease that will develop. Indeed, considering the 
three classes of tauopathies (3R, 4R, 3R/4R), it is clear that while the protein material 
is the same, it must be assembled in specific conformations that end up causing 
distinct pathologies. Structural insights into filaments made of recombinant tau 
isoforms proved that at least three types of fibrils exist, each one with individual 
characteristics: 3R aggregates, 4R aggregates and mixed aggregates composed of 
both types of isoforms that co-assemble into heterogeneous amyloids182. Mutations 
also affect the conformational properties of the fibrils, as they interfere with the 
hydrophobic and long-range interactions involved in fibrils formation. Indeed, using 
circular dichroism and spectroscopy techniques, Frost et al., showed that aggregates 
composed of wild-type or mutated (P301L/V337M) tau have different secondary 
structures and morphology187, with the mutated fibrils showing a peculiar curved 
morphology and lacking the twisted appearance of wild-type fibrils. One of the first 
conformers to be recognized as strain and characterised comes from the seeded 
aggregation of recombinant wild-type tau with pre-formed fibrils made of recombinant 
P301L/V337M tau. After some rounds of aggregation, a new conformer termed WT* 
was produced189. It is composed of wild-type protein, but its tertiary structure is 
strikingly similar to the mutated protein used as template. Other synthetic strains were 
obtained from the exposure of RD-tau expressing cells to synthetic fibrils produced in 
different chemical environments, and 2 out of 20 showed differences in inclusion 
morphology, aggregate size, subcellular localization, and extended also to 
biochemical properties, like protease sensitivity, seeding capacity and toxicity18. 
Concerning human tauopathies, Guo et al., [190] identified striking differences in the 
morphological structure of AD-seeded fibrils compared to in vitro ones, which affected 
their seeding potency and deposition pattern. This phenomenon is not limited to AD; 
indeed, inoculation of mice transgenic for human wild-type tau (ALZ17) with brain 
extracts from patients with different tauopathies recapitulated the major features of 
each disease (AGD, PSP, CBD)167. AD shows the highest homogeneity in strain 
composition, probably correlated to the existence of a predominant strain, whereas 
other diseases had strong interpatient variations, with at least two individual strains 
identified (PSP, AGD). As seen before, strain propagation occurs also in non-
transgenic mice. When brain extracts from patients with 4R and mixed tauopathies 
(AD, PSP, CBD) were inoculated in non-transgenic mice, specific inclusions formed 
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in different subcellular localization according to the type of biological sample. AD-tau 
induced a thread-like pathology mainly in axons and triggered the aggregation of both 
3R and 4R endogenous tau, while CBD seeds induced frequent perykarial pathology 
made predominantly of 4R tau. Among PSP strains, one in particular that came from 
the frontal cortex of the patient was found to be uniquely aggressive, with a very fast 
rate of spreading throughout the brain. Although showing variable seeding potency, 
all the three groups of strains, maintained cell specificity for neurons or glia as in the 
corresponding disease, such that only PSP and CBD samples induced astroglial and 
oligodendroglial pathology with coiled bodies that closely resemble their human 
counterparts. 
 
1.3.3.1. Ultrastructural differences of brain-derived tau filaments 
 
Thanks to the use of cryo-EM as a powerful technique to image protein aggregates, 
the structures of tau filaments from patients with AD, PiD and chronic traumatic 
encephalopathy were determined at the atomic level (3.5 Å) [83, 263, 264]. In all 
cases, the core of the filaments is made up by the repeated region and the rest of 
protein forms the fuzzy coat; however, the different interactions between short b 
elements result in distinct types of filaments packing.  
Tau aggregates in AD come mainly as paired helical filaments (PHFs), but a portion 
of other structures called straight filaments (SFs) is present. Both 3R and 4R tau 
isoforms are involved in the aggregation process and form mixed fibrils equally 
incorporating the two subgroups of isoforms. This peculiar situation is made possible 
by the fact that the fibrils core is formed only by the repeats R3 and R4, while the 
repeat R2, which is present only in 4R tau, is not involved. PHFs and SFs share a 
common structure of the core, shaped like the letter C. The difference in the overall 
arrangement of the fibrils come from ultrastructural diversities in the way 
protofilaments interact with each other. In PHFs, the C-shaped subunits pair up 










Moreover, the comparison between PHFs and SFs from patients with either sporadic 
or inherited AD indicated that there is no structural difference between individuals with 
AD [265].  
On the contrary, PiD filaments incorporate only 3R tau. The core consists of the 
residues 254-378, including repeats R1, R3 and R4. The b-elements of PiD filaments 
are arranged to form the letter J, and this particular fold is responsible for the ability 
of PiD aggregates to seed only 3R tau. Indeed, due to the amino acid composition, 
the side chains of the repeat R2 do not pack properly in this structure. When tau is 
folded into a J shape, Ser262 is buried in the interior of the aggregate, and cannot be 
phosphorylated. Indeed, in PiD no phosphorylation of Ser262 is detected. Preliminary 
evidence suggests also that, as for AD, also PiD patients share the same fold of the 
aggregates.   
Falcon et al. analysed also the structure of tau aggregates found in patients with 
chronic traumatic encephalopathy (CTE) [264]. Differently from the other tauopathies, 
in CTE the aggregation of tau is most probably triggered by mechanical stimulation, 
such as repeated injury. All six isoforms take part to the formation of the filaments. As 
in AD, the residues that form the core of the fibrils assemble into two C-shaped 
protofilaments; however, the different arrangements of some of the b-elements create 
a hydrophobic cavity that is not present in AD filaments and that seems to incorporate 
some cofactors.  
These structural data clearly show that the morphology of the aggregates vary among 
pathologies, although the reasons behind this phenomenon are yet to be clarified. 
Nevertheless, many information on tauopathies were obtained using synthetic 
amyloids, produced in vitro from either full-length or truncated tau constructs (K18, 
K19). When analyzing the ultrastructural details of AD fibrils, Fitzpatrick et al.[83] 
found that the packing of the core requires an interaction between the hexapeptide 
306VQIVYK311 and the residues 373-378. This last segment is not present in K18 and 
K19 constructs, which end at amino acid 372; therefore, their final assembly is 
different from that of PHFs and SFs from AD and should be used with caution when 
extrapolating in vitro results to tau aggregation in vivo. Moreover, the use of heparin 
as a cofactor to help the polymerization of recombinant tau in vitro leads to the 
obtainment of conformers that do not represent those found in patients [266]. Both 
2N3R and 2N4R isoforms were considered. In the presence of heparin, 2N4R formed 
polymorphic aggregates with at least four different conformers with a common kinked 
hairpin fold. Heparin-induced 2N3R amyloids were more homogeneous, with an 
ordered core mad of the third repeats of two parallel tau monomers. Fig. 1.11 shows 
the schematic representations of all tau folds studied with cryo-EM. It is evident that 
there are strong differences between synthetic and patient-derived filaments, both in 






Fig. 1.11. Comparison between the structures of protofilaments from AD and PiD with those of 
heparin-induced filaments of 2N4R (snake, twister and jagged) and 2N3R tau [266].   
 
Taken together, these data provide unifying neuropathological criteria to help 
distinguishing among tauopathies, and support the idea that the existence of distinct 
conformers of tau aggregates might underlie different disorders.  
 
1.3.4. Release and cell-to-cell transfer of tau aggregates 
 
Secretion of tau occurs in physiological conditions and independently of tau 
pathology. The mechanisms are still poorly understood, but there are many pathways 
involved. Around 90% of tau is released in a monomeric, non-phoshorylated form, 
often as a consequence of neuronal hyperexcitability [267]. Exosomes and 
ectosomes are also involved in the secretion of both soluble and fibrillar tau. 
Aggregates of ∆K280-RD tau were found in exosomes of overexpressing N2a cells, 
and they were shown to take part to the cell-to-cell spreading of the amyloids [268]. 
In addition, vesicles containing tau with seeding activity were found not only in brains 
of transgenic mice [269], but also in CSF and interstitial spinal fluids of both animal 
models [270] and patients [268]. In some cases, the seeded activity was limited to the 
acceleration of soluble oligomers formation and hyperphosphorylation rather than the 
induction of actual pathology [271]. Anyway, all these studies corroborate the 
hypothesis that extracellular vesicles are in some ways implied in prion-like 
propagation of tau pathology. 
Other mechanisms require direct contact between cell cytoplasm through 
membranous connections called tunnelling nanotubes. Although their existence has 
been called into question, mainly because of the lack of specific markers that identify 
them as independent structures, their role in transferring tau amyloids seems to be 
definitively assessed [272, 273]. Besides having been found inside TNTs, tau fibrils 
promote the formation of new nanotubes, as if they were boosting their own 
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transcellular spreading between neurons. Monomeric tau might also be a component 
of the nanotubes themselves, since immunofluorescence analysis revealed that tau 
appears besides filaments of actin and myosin in these structures.  
 
1.4. Cellular prion protein as a receptor for amyloids  
 
Among the functions of PrPC that have been discovered so far, one of the most 
intriguing is the ability of the cellular prion protein to act as a receptor and signal 
transducer for a variety of disease-related proteins [274-276]. Strikingly, all of them 
show an enrichment in ß-sheet elements as a common feature. The first protein for 
which this mechanism proved valid is indeed the counterpart of the cellular prion 
protein, its pathogenic conformer PrPSc. Besides being a substrate for prion-templated 
conversion, PrPC plays an active role in mediating the toxic signalling of PrPSc without 
changing its conformation. The interaction between the two partners does not involve 
specific sequences, but rather macroscopic structures, as for example secondary 
structure elements like ß-sheets. This is clearly deducible from the fact that PrPC from 
different animal species (hamster, human, bovine, cervid) transduced the toxic 
signalling of mouse PrPSc as efficiently as mouse PrPC, meaning that the interplay is 
independent of the primary sequences [274]. Actually, the binding partner of PrPC can 
be also a completely different protein, as long as ß-sheets are present; indeed, in the 
same paper the authors reported that oligomeric Aß was able to induce apoptosis 
through a signalling cascade activated by PrPC, and that this effect could be blocked 
by targeting the amyloids with an oligomer-specific antibody (A11). Another way of 
impairing the Aß-induced apoptosis was to use truncated PrPC forms, missing either 
the N-terminal segment (amino acids 27-89) or the C-terminal GPI-anchor. Moreover, 
when fusion peptides composed of the N-terminus of PrPC and the Fc portion of 
human IgG were added to the plates, Aß bound to them and the toxic effect was 
abrogated. Taken together, these findings suggest that the actual binding between 
PrPC and ß-sheet rich proteins occur through the N-terminal portion of the protein, 
while the GPI anchor is needed to activate the signalling cascade responsible for the 
toxic phenotype. Several studies focused on the identification of the specific regions 
mediating the interaction with Aß oligomers, and came up with slightly different 
results, that see the cluster of basic residues (amino acids 23-31, and specifically the 
KKRPK sequence) and the segment from amino acids 95/98 to 110 as the proper 
binding site [204, 277]. A third segment spanning residues 136-158 has been also 
identified, although only in PrPSc-induced signalling [278, 279]. As for the identity of 
the molecular interactors, Aß-induced toxicity seems to require the metabotropic 
glutamate receptor 5 (mGluR5), the tyrosine kinase fyn, and the NR2B subunit of 
NMDA receptor, which becomes phosphorylated and dysregulates the receptor’s 
functions [280, 281] (Figure 1.12). Additionally, the N-terminal domain of PrPC can 
penetrate the plasma membrane exploiting the polybasic regions, and once inside the 
cytoplasm it acts as a protein transduction domain [282, 283]. 
In vivo experiments proved controversial in supporting the notion that this mechanism 
really occurs in diseased brains. On the one hand, Strittmatter’s group showed that 
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PrP-knockout mice treated with Aß amyloids do not suffer from suppression of long-
term potentiation (LTP) as their wild-type counterparts, and treatment with anti-PrPC 
antibodies rescued the phenotype of wild-type mice [284]. On the other hand, Balducci 
et al. did not report any difference in long-term memory between wild-type and PrP-
knockout mice, raising questions on the actual importance of PrPC-induced signalling 
[285]. One possible explanation for these contrasting data is that in both cases Aß 
oligomers were produced form synthetic material, and preparations may vary between 
different laboratories [286]. It might be that only some specific conformers of Aß are 
able to trigger their signalling cascade through PrPC [287]. This speculation is indeed 
quite plausible, given that similar divergences were found when considering the 
interaction of PrPC with another ß-sheet-enriched amyloid, a-synuclein fibrils. a-
synuclein is the major component of Lewy bodies, the main pathological hallmark of 
Parkinson’s disease. Contrary to Aß, which remains extracellular, a-synuclein 
aggregates are internalized by neurons mainly by receptor-mediated endocytosis and 
exert their toxic functions from the inside of the cells. Known receptors include the 
transmembrane protein lymphocyte-activator gene 3 (LAG3), neurexin, amyloid ß 




Figure 1.12. Signalling cascade activated by the binding of Aß oligomers to PrPC [290]. Binding 
of Aβo to cellular prion protein (PrPC) triggers mGluR5-dependent signaling events which proceed 
through fyn kinase.  
 
Recently, our group pointed at PrPC as another putative receptor that facilitates the 
entrance of a-synuclein amyloids in cells [205].  In this work, a more consistent uptake 
of synuclein fibrils was observed in N2a cells constitutively expressing PrPC compared 
to the same cell line ablated for PrPC, and also in primary cortical neurons. SPR 
analysis produced two distinct constants for PrPC-synuclein binding, which may reflect 
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the high disomogeneity of the fibrils preparation used. Indeed, aggregates obtained 
by in vitro fibrillization had been subjected to sonication that breaks longer fibrils 
randomly into smaller fragments and increases the variability of the final products. 
Different species, i.e. long vs. short fibrils, might show different propensities to bind to 
PrPC and to exploit its activity as receptor protein to gain cell entrance. Short fibrils 
showed the strongest binding to PrPC and their uptake was the most affected by the 
knock-out of PrP, while longer fibrils were internalized with more difficulty also in PrP-
expressing cells. Short fibrillar species should not be confused with oligomers, as the 
former maintain the ordered ß-sheet organization typical of fibrils despite being 
smaller, while the latter have their own peculiar structure. Structural differences 
between the two species might explain why oligomeric a-synuclein was reported to 
not bind to PrPC and to induce the same detrimental effects in both wild-type and PrP-
null mice [291]. On the contrary, when using fibrils preparations, the role of PrPC in 
the spreading of synuclein pathology is clearly assessed. Although not mandatory for 
the diffusion of the pathology in the brain, expression of PrPC increases the rate of 
transport of the aggregates between cells and result in a higher accumulation of PK-
resistant synuclein amyloids in many districts of the CNS [205, 292]. As already seen 
for Aß oligomers, the toxic effects of synuclein fibrils proceed through the signalling 
cascade initiated by mGluR5 and dependent on fyn kinase and NMDAR2B [293]; 
however, since Lewy bodies are intracellular, a new model was proposed in which 
PrPC takes part to the endocytic pathway that brings synuclein inside the cells after a 
short stay in the endolysosomal compartment [205, 294].  
All these findings underline that a close link exists between the prion protein functions 
and its role in the spreading of different neurodegenerative diseases other than TSEs. 
From a therapeutic point of view, the discovery of a shared mechanism underpinning 
the spreading of very different diseases like PD and AD is of extreme importance, as 
it allows the development of common therapeutics directed against PrPC that might 
be able to delay the neurotoxicity of many protein aggregates and block their 
spreading. Given these very promising results, the question arises if other prion-like 
disorders like tauopathies take advantage of the prion protein to disseminate in the 
brain and cause degeneration, and if any treatment targeting PrPC would in some way 














AIM OF THE RESEARCH 
 
 
One of the most intriguing challenges posed in the field of neurodegenerative 
diseases concerns the possibility of finding some sort of “common ground” between 
disorders that have been so far considered as separate entities. Several in vitro and 
in vivo studies showed that there is a cross-talk between neurodegeneration-related 
proteins, which appear to share some key features that reflect into similar disease 
progression. In this perspective, the identification of receptor proteins that could be 
involved in more than one neurodegenerative disorder would offer a completely new 
point of view on these pathologies, as well as interesting therapeutic targets to be 
used against an array of disorders.  
The cellular prion protein PrPC has been reported to bind to both amyloid ß and 
synuclein fibrils, to mediate their toxic effects and, in the case of synuclein, also to 
promote their entrance into the cell cytoplasm. Therefore, in this thesis we focused 
our attention on whether PrPC might exert the same effect on tau fibrils. In particular, 
we evaluated two aspects of the possible interaction between the cellular prion protein 
and tau amyloids: 
 
i. The ability of PrPC to facilitate the internalization of tau K18 amyloids in 
neuroblastoma cell lines. Taking advantage of the tau truncated fragment 
K18, widely used as a model for the study of tauopathies, we first assessed 
the existence of an interaction between the cellular prion protein and the 
amyloids. Next, we evaluated the internalization of tau fibrils in cell lines 
that either express or not the prion protein on the cell surface. Potential 
therapeutic approaches were evaluated by targeting specific domains of 
PrPC with antibodies.  
 
 
ii. To promote PrPSc clearance in prion-infected cell lines mediated by tau K18 
fibrils. As observed by Aulic et al. [205], synuclein amyloids promote the 
clearance of PrPSc in ScN2a cells, most probably through the inhibition of 
prion conversion. We investigated if tau fibrils show the same propensity to 
decrease the prion levels in prion-infected cells, and we evaluated the 
contribution of the cellular degradation pathways to the tau-induced PrPSc 










 MATERIALS AND METHODS 
 
 
2.1. Tau K18 expression and purification 
 
Expression and purification of recombinant tau K18 fragment were performed as 
previously described. Briefly, pET-11a expression vector containing the sequence 
encoding for tauK18 was transformed into E.coli BL21(DE3) strain (Stratagene), and 
protein expression was achieved according to the following protocol: an overnight 
culture of E.coli BL21(DE3) was inoculated in 2L of Luria-Bertani medium 
complemented with ampicillin 100µg/mL and grown at 37°C until 0.8 O.D.600, when 
protein expression was induced with 0.8 mM IPTG and the temperature was lowered 
to 30°C to minimize degradation. The cells were harvested by centrifugation after 5 
hours from induction. Lysis was performed at 4°C using PandaPlus Homogenizer in 
the presence of protease inhibitors (Complete™ ULTRA Tablets, EDTA-free, glass 
vials Protease Inhibitor Cocktail, Roche) and the supernatant containing the 
recombinant protein was subjected to a boiling step that precipitates the majority of 
the proteins except for tau. The supernatant was then loaded onto a 5 mL HiTrap SP 
FF chromatographic column (GE Healthcare) in binding buffer (20 mM MES, 50 mM 
NaCl, 1 mM EDTA, 0.1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF, pH 6.8) and eluted 
with a linear gradient from 0% to 60% of elution buffer (20 mM MES, 1 M NaCl, 1 mM 
EDTA, 0.1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF, pH 6.8). Fractions were analysed 
on SDS-PAGE for protein content, and those containing  tauK18 were pooled 
together, loaded onto gel filtration column (Superdex 200 26/60, GE Healthcare) and 
eluted with PBS pH 7.4. Purified protein was analysed by SDS-PAGE, dyalized 
against water and lyophilized.  
 
2.2.  Fibrillization of tauK18 
 
All solutions were sterilized by filtration with a 0.22 µm filter prior to use. Reactions 
were prepared in a 96-well black plate with transparent bottom (BD Falcon) in a final 
volume of 200 µL per well. Fibrillization reaction was composed as follows: tauK18 
0.5 mg/mL, heparin 10 µg/mL, DTT 0.1 mM, PBS 1X pH 7.4. Due to its toxicity to 
cultured cells, 10 µM Thioflavin T (ThT) was added only in 4 wells that were used to 
monitor the aggregation reaction in real-time. Each well contained also a 3-mm glass 
bead (Sigma). The plate was covered with sealing tape (Fisher Scientific) and 
incubated at 37°C under orbital shaking (50 seconds of shaking at 400 rpm followed 
by 10 seconds of rest) on FLUOstar Omega (BMG Labtech) microplate reader. 
Fluorescence was monitored every 30 minutes by bottom reading at 444 nm of 
excitation and 485 nm of emission. The reaction was stopped after 15 hours, when 
fluorescence reached plateau. Newly formed aggregates were pelleted by 
ultracentrifugation (55000 rpm for 1 hour at 4°C), resuspended in an equal volume of 
sterile PBS and stored at -20°C. Before use, aliquots were thawed and sonicated for 
5 minutes in an ultrasonic bath (Branson 2510). 
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2.3. AFM analysis 
 
AFM analysis was performed in accordance with the method previously described 
[435]. Ten μL of fibril solution was deposited onto a freshly cleaved piece of mica and 
left to adhere for 30 min. Samples were then washed with distilled water and blow-
dried under a flow of nitrogen. Images were collected at a line scan rate of 0.5-2 Hz 
in ambient conditions. The AFM free oscillation amplitudes ranged from 25 nm to 40 
nm, with characteristic set points ranging from 75% to 90% of these free oscillation 
amplitudes. AFM data were analysed with Gwyddion (gwyddion. net). 
 
2.4. Cytotoxicity assay 
 
The cytotoxic effect of tauK18 fibrils was evaluated by measuring cellular redox 
activity with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). 
30000 N2a cells/well were cultured in 96-wells plates and treated with different 
concentrations of tauK18 sonicated fibrils added directly in the cell culture medium. 
Following 72-hours incubation, the cytotoxic effect was assessed by measuring 
cellular redox activity, following the manufacturer’s (Sigma) instructions. 
 




Experiments were performed on 2,5-months old transgenic male and female rats (line 
SHR72), and on 5 months old transgenic mice (line R4m7) both expressing human 
truncated 4R tau protein (amino acids 151-391) consisting of the four microtubule 
binding domains. Animals, chosen in random, were injected unilaterally with 3µL for 
rats and 2 µL for mice of insoluble tau fraction (n=2), K18 sonicated (n=3) or K18 non-
sonicated (n=3). All animals were housed under standard laboratory conditions with 
water and food ad libitum. All experiments were performed in accordance with the 
Slovak and European Community Guidelines, with the approval of the Institute’s 
Ethical Committee and study has been approved by the State Veterinary and Food 




Rats and mice were anesthetized with 1.5% to 2% isoflurane (Florane) and the 
temperature of the animals was maintained at 37°C. Then animals were fixed to 
stereotaxic apparatus (Kopf Instruments, California, USA) and UltraMicroPump III 
(UMP III) and Micro4 Controller (World Precision Instruments, Florida, USA) were 
used for applying of substances. UMP III uses microsyringes to dispense 
nanoliter/microliter sample volumes. Animals received unilaterally 3 µL (rat) or 2 µL 
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(mice) of sarkosyl insoluble tau (concentration 500ng/µL) or of K18 sonicated/non-
sonicated fibrils (concentration 500ng/µL, 300ng/µL). 
Stereotaxic coordinates for the injection were characterized using stereotaxic atlas 
(“The rat brain in stereotaxic coordinates”, Paxinos and Watson) and also was taken 
into account the age and the strain of animals. Stereotaxic coordinates for the injection 
into hippocampus of rats were A/P: -3.6 mm, L: -2.0 mm, D/V: 2.9 (females) or -3,1 
(males) mm from bregma. For mice the stereotaxic coordinates were A/P: -2.1 mm, 
L: -1.2 mm, D/V: -1.8 mm from bregma (Paxinos and Watson, 1996). The needle 
remain in place at the injection site for an additional 5 min before the cannula was 
removed slowly (over 2 min). The skin was sutured and the animal was returned into 
home-cage and monitored until fully recovered. Post-operative care included the non-
steroidal anti-inflammatory drugs. 
 
2.6. Preparation of fluorophore-labeled fibrils 
 
TauK18 fibrils were conjugated to AlexaFluor 488 NHS Ester (Thermo Fisher) 
following the protocol described by Karpowicz et al.[295] Briefly, tauK18 fibrils were 
pelleted by ultracentrifugation and resuspended in carbonate buffer (0.1 M NaHCO3, 
pH8.3). AlexaFluor 488 was added directly to the resuspended fibrils, which were then 
incubated for 1 hour at 25 °C under mild shaking (300 rpm). The unbound fluorophore 
was removed by four dialysis steps in sterile PBS using gamma-irradiated Slide-A-
Lyzer dialysis cassettes with a molecular weight cut-off of 10 kDa (Thermo Fisher). 
Fluorescent fibrils were aliquoted and stored in the dark at -20°C. 
 
2.7. Preparation of biotinilated fibrils 
 
Biotinilated fibrils were produced accordingly to the manufacturer’s (Sigma) 
instructions. TauK18 fibrils were pelleted by ultracentrifugation and resuspended in 
carbonate buffer pH 9.5 to a final concentration of 20 mg/mL. Biotin NHS Ester 
(Sigma) was added to the resuspended fibrils with gentle stirring, and the solution was 
incubated for 4 hours at room temperature. Unbound biotin was removed by four 
dialysis steps in PBS using Slide-A-Lyzer cassettes with a molecular weight cut-off of 
3.5 kDa. Biotinilated fibrils were aliquoted and stored in the dark at -20°C. 
 
2.8. Pull-down assay 
 
Neuro2a cells were lysed in lysis buffer (0.1% NP40, 50 mM TrisHCl pH 8, 150 mM 
NaCl) containing one tablet of Complete™ ULTRA Tablets, EDTA-free, glass vials 
Protease Inhibitor Cocktail (Roche). Total protein content was quantified using 
bicinchoninic acid protein (BCA) quantification kit (Pierce). 1 mg of total protein 
content was diluted in lysis buffer to a final volume of 500 µL, then biotinylated tauK18 
fibrils were added to a final concentration of 2 µM. Samples were left standing on a 
rotor wheel overnight at 4°C. The day after, 30 µL were collected from each sample 
and stored at -20°C for further analysis (input samples). 30 µL of neutravidin bead 
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slurry (NeutrAvidin Agarose Resins, ThermoFisher Scientific) were added to each 
tube, and the samples were incubated on the rotor wheel at 4°C for 4 hours. To 
precipitate the beads, the samples were centrifuged at 4°C for 2 minutes at 2000 rpm, 
the pellet was washed with three subsequent steps of resuspension in lysis buffer and 
centrifugation, and finally resuspended in 20 µL of Laemmli loading buffer. Samples 
were boiled for 10 minutes and centrifuged at 13000 rpm for 1 minutes to detach and 
pellet the beads, respectively. The supernatants were collected and stored at -20°C. 
 
2.9. Cell lines 
 
Mouse neuroblastoma cells N2a were kindly provided by Prof. Chiara Zurzolo (Unité 
de traffic membranaire et pathogenèse, Institute Pasteur, Paris, France). N2aPrP KO 
cells were kindly provided by professor Gerold Schmitt-Ulms (Tanz Centre for 
Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, 
Canada), for which they used the CRISPR-Cas9-Based Knockout system to ablate 
the expression of PrP protein [293]. ScN2a cells are clones persistently infected with 
the RML prion strain as described by Prusiner’s group [437] or with the 22L prion 
strain. Cells were grown at 37°C and 5% CO2, in minimal essential medium (MEM) + 
glutamax (Thermo Fisher Scientific Inc.), supplemented with 10% fetal bovine serum, 
1% non-essential aminoacids, and 100 units/ml penicillin and 100 μg/ml streptomycin. 
 
2.10. TauK18 fibrils infection in cell lines 
 
2uM of tauK18 amyloids was added to the cell culture medium of N2a, N2aPrP KO 
and ScN2a cell lines in 10 cm plates, and incubated for a variable amount of time 
according to the specific experimental setting (ranging from 1 day to 6 days). For the 
evaluation of PrPSc clearance in ScN2a cell line, cells were split and maintained for 
five additional passage in fibrils-free cell culture medium. For fluorescence 
quantification of amyloids internalization, cells were plated in 24-wells plates on 12 
mm coverslips and incubated with Alexa488-labeled fibrils for 24 – 72 hours. 
 
2.11. Trypan blue quenching of non-internalized fibrils and imaging  
 
30000 cells were cultured on each coverslip and treated with 2 µM Alexa488-labeled 
tauK18 fibrils. Before fixation, cells were washed twice with sterile PBS and incubated 
for 5 minutes with a sterile 1:1 solution of Trypan Blue : PBS. As shown by Karpowicz 
et al., Trypan Blue quenches green fluorescence through an energy-transfer 
mechanism, but being unable to enter alive cells, only the fluorescence coming from 
non-internalized fibrils is quenched.  
Cells were then rinsed three times with sterile PBS and fixed for 10 minutes with 4% 
paraformaldehyde/PBS. After three washing steps, cells were permeabilized for 5 
minutes with 0.2% Triton X-100/PBS, rinsed again with PBS and incubated for 1 hour 
with HCS Blue Cell Mask (ThermoFisher Scientific) diluted 1:1000, a specific dye that 
labels the whole cell cytoplasm. Coverslips were mounted in Fluoromount-GTM 
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(ThermoFisher Scientific) and stored at 4°C for confocal fluorescence microscopy. 
Images were acquired using a Nikon confocal microscope (Nikon C1).  
 
2.12. Inhibition of tauK18 internalization using POM monoclonals 
 
Anti-PrPC monoclonal antibodies were kindly provided by Prof. Adriano Aguzzi 
(Institute of Neuropathology, University of Zürich). POM monoclonals include a series 
of antibodies directed against multiple epitopes distributed on the whole sequence of 
PrPC [296]. For the inhibition of tauK18 fibrils uptake, three antibodies were 
considered: POM12, which binds a degenerative epitope within the octarepeat 
sequence of PrPC; POM3, which targets the amino acids 95-100 (HNQWNK) near the 
centre of PrPC; POM4, which binds a conformational epitope formed by the very C-
terminal (around amino acids 220) and a middle part of the protein (amino acids 121-
134). N2a cells plated on coverslips were pre-treated with each POM antibody (15 
µg/mL) for 1 hour at 37°C, followed by incubation with Alexa488-labeled tauK18 fibrils 
for 24 hours. Coverslips were processed and mounted as described above. To check 
the binding of POM antibodies to membrane PrPC, cells treated with POM antibodies 
for 1 hour were fixed with 4% paraformaldehyde:PBS for 10 minutes, then blocked 
with 2% FBS for 30 minutes and incubated with Alexa594-conjugated goat anti-mouse 
IgG diluted 1:200 for 1 hour. 
 
2.13. Uptake quantification 
 
The uptake quantification was performed in blind on more than 200 cells in three 
independent experiments. Random fields on each coverslip were captured at 63x 
magnification (zoom 3X) using Nikon confocal microscope. Images were acquired as 
30 - 40 z-stacks of 0.27 µm, 526 x 526, and subsequently deconvolved with a 3D 
deconvolution algorithm (in blind) of the NIS Elements software. Deconvolution was 
applied only to the green channel, as it allows a better separation of the green dots 
representing the fibrils. Deconvolved images were analysed using Volocity 
Workstation (PerkinElmer, version 4.1) and internalized fibrils were counted using a 
home-made script which intersects the objects recognized in the green channel with 
the 3D reconstruction of the cellular volume (blue channel). To discriminate the 
signals corresponding to fibrils from the background, we used the volume of a single 
monomer of synuclein as a threshold. Synuclein is very similar to tau K18 in terms of 
molecular weight and unfolded structure. The volume of a monomer in its multiple 
conformations was obtained from Zhang et al. [297] 
 
2.14. Membrane immunostaining of PrPC 
 
N2a cells seeded on coverslips were treated for 24 – 72 hours with 2 µM of tauK18 
fibrils. Surface staining of PrPC was performed as described in Stincardini et al.[298]. 
Cells were incubated with W226 antibody diluted 1:250 in Opti-MEM (Life 
Technologies) for 15 minutes at 4°C, followed by washing in PBS and fixation with 
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4% paraformaldehyde:PBS for 10 minutes. Coverslips were then washed three times 
with PBS, incubated with blocking solution (2% FBS in PBS) for 30 minutes and 
incubated with Alexa-594 conjugated goat anti-mouse IgG (Invitrogen) diluted 1:200 
in blocking solution. Finally, nuclei were counterstained with DAPI (1:1000). 
Coverslips were mounted in Fluoromount-GTM (ThermoFisher Scientific) and stored 
at 4°C. Images were acquired with Nikon confocal (Nikon C1) at 63x magnification, 
both as 2D-images of medial planes and series of 30-40 z-stacks 0.27 µm, 526x526.  
 
2.15. Quantification of membrane staining 
 
Quantification of membrane staining was performed with Volocity Workstaton 
(PerkinElmer) on 2D images. Image segmentation consisted first of nuclei 
identification by the DAPI signal, and selection of the region of interest by the Alexa-
594 signal. Mean fluorescence intensity values of Alexa594-conjugated anti-PrP 
antibody were measured for more than 600 objects per coverslip, and weighted 
averages were calculated in order to identify any difference between untreated and 
treated samples. To confirm that 2D quantification is representative of the situation of 
the whole cell membrane, the same analysis was performed on a number of 3D z-
stacks from both untreated and treated samples. As an additional control, N2a cells 
were treated with 10 µM chlorpromazine[298], and a reduction of PrPC membrane 
levels was observed both with 3D and 2D images.  
 
 
2.16. Quantification of total PrPC levels by Western Blotting 
 
Total protein contents of N2a untreated and treated with 2 µM of tauK18 fibrils were 
quantified using bicinchoninic acid protein (BCA) quantification kit (Pierce). Fifty µg of 
total proteins were used and complemented with 5X loading buffer in a ratio 1:5. The 
samples were boiled at 100°C for 10 minutes, loaded onto a 12% Tris-Glycine SDS-
PAGE gel and transferred onto Immobilon P PVDF membranes (Millipore) for 2 hours 
at 4°C. The membrane was blocked in 5% non-fat milk and incubated overnight at 
4°C with human anti-PrP antibody D18 diluted 1:1000. The membrane was washed 
three times with TBS buffer additioned with 0.2% Triton X-100, incubated for 45 
minutes at room temperature with goat anti-human IgG conjugated with horseradish 
peroxidase and developed with the enhanced chemiluminescent system (ECL, 
Amersham Biosciences). After the acquisition, the membrane was incubated for 30 
minutes at room temperature with anti β-actin (1:10000, A3854 Sigma-Aldrich), which 
is used as a normalizer. Images were acquired with Uvitec Alliance (Cambridge) and 
densitometric analysis was performed using Uviband analysis software. Data are 






2.17. Total RNA extraction and RT-PCR analysis 
 
The total RNA extraction was performed using PureLink RNA MiniKit with TRIzol® 
Reagent  (Life Technologies) following the manufacturer’s instruction. Briefly, control 
cells and cells treated with tauK18 fibrils were washed twice with PBS 1X and lysed 
using the TRIzol® Reagent. Following RNA isolation, a DNase I digestion was 
performed using 1 unit of enzyme per μg RNA for 15 min at room temperature, and 
RNA clean-up was implemented using RNeasy spin columns following the 
instructions. RNA concentration was determined using the NanoDrop system 
(Thermo Scientific). First-strand cDNA was synthesized using 3 μg of total RNA in a 
20 μL reverse transcription reaction (RT+ samples) mixture following the instructor 
manual. For each sample a non-retrotranscribed sample was carried along as a 
negative control (RT− sample). 
The cDNA was diluted to 10 ng/μL final concentration prior to Real-Time PCR 
reactions. 1 ng of cDNA was added to the reaction mix including 2× iQ™ SYBR® 
Green Supermix (Bio-Rad Laboratories, Inc.), 400 nM of the corresponding forward 
and reverse primer (Sigma), and quantified in technical duplicates on an iQ5 
Multicolor Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.). 
After initial denaturation for 3 min at 95°C, 45 cycles were performed at 95°C for 10 
sec and 60°C for 1 min. Differential gene expression of was normalized to GAPDH 
expression. RT– controls were included in the plates for each primer pair and sample. 
The relative expression ratio was calculated using the ΔΔCT method [299]. 
Significance was calculated with the unpaired student t-test (p < 0.05). The primers 
used for RTqPCR reactions are listed in Table 2.1. 
 
Gene Chromosome Primer sequence Amplicon 
length (bp) 
GAPDH 11 F: CCTGCACCACCAACTGCTTA  
R: CTGTCACCTTCACCGTTCC  
 
74 
PRNP 2 F: GAGACCGATGTGAAGATGATGGA  





2.18. Proteinase K digestion  
 
ScN2a RML and 22L cell lysates (250 µg) were treated with with 20 μg/mL of 
proteinase K (PK) for 1h at 37°C. The reaction of proteolysis was stopped by the 
addition of phenylmethyl sulphonyl fluoride (PMSF) in a final concentration of 2mM. 
Immediately after, the samples were centrifuged at 55000 rpm, the supernatant was 
discarded and the pellet was resuspended in 2x loading buffer, boiled for 10 min, and 
resolved by 12% SDS-PAGE. The same protocol as above was used for the blotting 
procedure and the acquisition of the images. The antibodies used to visualize PrPSc 
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signal are mouse monoclonal anti-PrP W226 (diluted 1.1000 in blocking solution) and 
goat anti-mouse IgG conjugated to horseradish peroxidase (DAKO, diluted 1:1000 in 
blocking solution).  
 
2.19. PNGase F treatment 
 
PNGase F treatment (New England Biolabs) was performed on control and K18-
treated ScN2a cell lysates. Twenty µg of total proteins were incubated with 1 µL of 
Glycoprotein Denaturating Buffer (10X) and water to reach a total reaction volume of 
10 µL, then the mix was heated at 100 °C for 10 minutes to denature the proteins. 
The solution was chilled on ice and centrifuged for 10 seconds, then complemented 
with 2 µl of GlycoBuffer 2 (10X), 2 µl of 10% NP-40, 6 µl of H2O and 1 µl of PNGase 
F. The solution was incubated overnight at 37°C. Deglycosylated proteins were then 
analysed by Western Blot. 
 
2.20. 3-methyladenine treatment 
 
3-methyladenine (Sigma) was dissolved in sterile water to a final concentration of 30 
mg/mL. ScN2a were first treated with K18 for 72 hours, and 3-MA at the concentration 
of 10 µM was added for the last 16 hours. Control consisted of untreated cells, with 
or without 3-MA. Cells were collected, lysed in lysis buffer and subjected to PK 
digestion and Western Blot analysis. 
 
2.21. Ammonium chloride treatment 
 
Ammonium chloride (NH4Cl) was dissolved in sterile PBS. ScN2a were treated with 
K18 and 10 mM NH4Cl for 72 hours. Control consisted of untreated cells, with or 
without NH4Cl. Cells were collected, lysed in lysis buffer and subjected to PK digestion 



















3.1. Preparation of human tau K18 fibrils and structural characterization 
 
The K18 fragment of human tau protein that comprises only the microtubule-binding 
domain (amino acids 274-372) was produced in E.coli BL21(DE3) bacterial strain and 
purified with two subsequent chromatographic steps to yield a highly pure 
recombinant protein. A homology comparison of the human tau microtubule-binding 
domain with the same region of murine tau and rat tau (taxid: Mus musculus and 
Rattus norvegicus, respectively) showed that the amino acidic sequence is almost 
perfectly conserved among these species.  
Next, we set up a protocol to produce in vitro synthetic fibrils as described by Barghorn 





Figure 3.1. Expression and purification of human tau K18 fragment. (A) Tau K18 fragment belongs 
to the subclass of 4R isoforms and includes only the repeated regions that form the microtubule binding 
domain (spanning amino acids 244-372). Known pathogenic mutations are indicated underneath the 
structure, but only the wild-type construct was used in this study. (B) Plasmid used for expressing 
human tau K18 in E.coli BL21(DE3). (C) Homology comparison between the microtubule-binding 
domain of human tau and mouse tau and (D) human tau and rat tau. (E) Chromatogram obtained from 
the second purification step of tau K18 by size-exclusion chromatography. (F) Expression of 
recombinant human tau K18. 15% SDS-PAGE. Lanes 1 and 10: molecular mass marker; lane 2: whole 
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cell extract before IPTG induction; lanes 3, 4 and 5: whole cell lysate after IPTG induction; lanes 6 and 
7: pellet and supernatant after cell lysis by homogenization; lanes 8 and 9: pellet and supernatant after 
boiling; lane 11: purified tau K18 protein. 
 
The in vitro fibrillization assay allows a rapid and efficient misfolding of the 
recombinant soluble protein into fibrillar, amyloid-like structures enriched in ß-sheets. 
The aggregation process is monitored by checking the fluorescence of the dye ThT, 
which gives a strong fluorescence signal upon binding to amyloid fibrils. Once all the 
monomeric has been converted into fibrils, the ThT signal reaches the plateau phase 
and remains flat. In order to better characterise tau K18 propensity to aggregate, we 
tested the effect of three different concentrations of monomeric protein in terms of lag 
phase duration and maximum intensity of ThT signal (figure 3.2.) 
 
 
Figure 3.2. In vitro auto-aggregation kinetics of human tau K18. Three different concentrations of 
monomeric tau K18 were tested in the in vitro assay: 0.1 mg/mL (pink squares), 0.5 mg/mL (green 
circles) and 1 mg/mL (light blue triangles). To check for any possible unwanted contribution from the 
reaction components, a control condition without the recombinant protein was also included (red 
circles). Each fibrillization curve represents the average of three replicate wells. 
 
Higher concentrations of tau did not significantly alter the duration of the lag phase, 
which is already very short with the lowest protein concentration (around 1 hour). As 
expected, the maximum intensity reached by the ThT signal at the plateau was 
strongly influenced by the protein concentration, with a more consistent production of 
aggregates when higher amounts of substrate were used. We noticed that while the 
two lower concentrations of tau K18 converted into fibrils with the typical sigmoid 
pattern, a further increase of monomeric protein up to 1 mg/mL led to a kinetic curve 
resembling a double sigmoid, with an early plateau phase followed by a second 
growth phase and eventually by a definitive saturation.  
Given these observations, we chose 0.5 mg/mL as final concentration of tau K18 for 
further experiments, as it proved to best fit the requirements of both a highly 
reproducible fibrillization process and a consistent production of amyloid material. We 
let the reaction go for around 13 hours in order to reach the plateau and to have most 
of the soluble protein converted into long, mature fibrils (Fig. 3.3, panel A).  
The aggregates were then subject to a round of sonication for 5 minutes in order to 
break them into smaller species. Indeed, in AFM images of non-sonicated fibrils we 
 52 
could observe that, conversely to synuclein, tau aggregates formed in vitro tend to 
stick one to the other and form big clumps which cannot be easily internalized by 
cultured cells. Sonication not only disrupts these plaques, but also breaks most of the 
longer fibrils into small pieces, therefore increasing the homogeneity of the 




Figure 3.3. Production and characterization of human tau K18 fibrils. (A) Fibrillization curve of 
human tau K18 0.5 mg/mL, represented as average of three replicate wells. The dashed square 
indicates the timepoint at which the reaction was stopped and the aggregates collected and analysed 
by AFM before sonication. (B) AFM analysis of tau aggregates after 5 minutes of sonication and (C) 
length and height measurements of the fibrils.  
 
Before moving to cell culture studies, we checked the cytotoxicity of the fibril 
preparation using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. This rapid and effective test measures mitochondrial activity, that 
correlates with cell proliferation. The evaluation of any potential toxic effect of 
exogenously added material, tau fibrils in this case, is a crucial step in the 
individuation of the most suitable cell line for further experiments. Three different 
murine neuroblastoma cell lines (N2a) were exposed for 72 hours to four increasing 
concentrations of sonicated tau fibrils: 0.5 µM, 1 µM, 2 µM and 5 µM. We used wild-
type N2a, that physiologically express the cellular form of the prion protein, and N2a 
Prnp-/- (referred to as N2a KO in this work), in which the expression of PrPC has been 
ablated using the Crispr/Cas9 system (293S). Finally, we used also N2a cells 
persistently infected with the RML prion strain (ScN2a), which represent a useful tool 
to study prion replication. The assay did not reveal any significant reduction of cell 
viability after the exposure to the different concentrations of tau fibrils compared to 
control cells (Fig. 3.4), although N2aKO showed a slightly higher sensitivity to tau 
toxicity compared to their wild-type counterpart in all four cases. However, we cannot 
attribute the increased mortality rate of N2aKO solely to the toxicity of tau fibrils, as 
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PrPC is known to have neuroprotective roles and its ablation might result in a lower 
cell viability, independently of any exogenous agent. 
 
Figure 3.4. Toxicity of tau K18 aggregates in neuroblastoma cell lines. Three different 
neuroblastoma cell lines were treated with various concentrations of tau K18 fibrils for 72 hours. Results 
are represented as mean ± standard deviation of three independent experiments performed in six 
replicates. 
 
3.2. Synthetic tau K18 aggregates induce tau pathology in mouse and rat 
models 
 
In order to better characterise our synthetic tau aggregates, we performed a unilateral 
injection of K18 amyloids, both sonicated and non-sonicated, into the hippocampus 
of mice and rats overexpressing a truncated human 4R tau construct (Fig 3.5, A). This 
specific brain area was chosen because of its propensity to accumulate tau 
aggregates in tauopathies. Even though none of the animals showed any clinical sign 
of pathology after 3 months from injection, they were sacrificed and the brains were 
analysed immunohistochemically (IHC) with AT8 antibody. We were able to detect 
some tau pathology in all brain samples, with K18 sonicated fibrils being the most 
effective in inducing tau aggregation (Fig. 3.5, B-C). Compared to the effect of PHFs 
isolated from AD brain, synthetic fibrils induced a less robust tau pathology, and mice 
were more subjected to fibrils-induced aggregation than rats (Table 1). Importantly, 
all the aggregated tau detected is phosphorylated on Ser202 and Thr205. Tau 
pathology looked like tiny fibrils concentrated in the space close to the cell membrane 
but not filling the whole cytoplasm. Thus, our results confirm that K18 fibrils are able 
to initiate tau pathology in vivo. As synthetic fibrils might require more time to trigger 
aggregation, we did not sacrifice all the animals; specifically, some R4m7 mice 
injected with K18 fibrils are still alive and will be sacrificed after 6-8 months post-





Figure 3.5. Immunohistochemical staining for tau pathology in the hippocampus of R4m7 mice 
and SHR72 rats. (A) K18 sonicated and non-sonicated fibrils were injected unilaterally in the 
hippocampus of transgenic mice (R4m7) an rats (SHR72) overexpressing a 4R truncated construct of 
tau. Tau pathology, consisting of small NFTs and neurophil threads, was detected in the hippocampus 
of mice (B) and rats (C) after 3 months post-injection. Tau aggregates were stained with AT8 antibody, 
which recognizes tau phosphorylated on Ser202 and Thr205. PHFs extracted from AD brains were 





Table 3.1. Quantification of NFTs in mice and rats treated with tau K18 fibrils. 12 slides/animal 
were used for quantification.  
 
3.3. Tau K18 fibrils internalization in neuroblastoma cells is time- and 
concentration dependent 
 
Tau fibrils have been reported to enter many types of cell lines without the need for 
any transduction reagent like lipofectamine[301], which is a conditio sine qua non 
when the aim is to characterise the role of a possible receptor protein. Therefore, we 
directly added tau K18 fibrils to the cell culture medium and studied their uptake at 
different timepoints. 
To confirm the internalization of the exogenously added tau assemblies into cells, we 
took advantage of confocal microscopy and of an innovative approach first tested on 
synuclein aggregates by Karpowicz et al. [295]. According to this procedure, fibrils 
produced by in vitro aggregation of recombinant proteins are chemically conjugated 
to the succinimidyl ester of a fluorescent dye, in this case Alexa Fluor® 488, to yield 
a fluorescently-labelled product. Using this method, the aggregates are sonicated 
before the conjugation and are all equally labelled.  
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Non-internalized fibrils tend to deposit on the surface of the coverslip or to adhere to 
the membrane, making it difficult to discriminate if the aggregates have really entered 
the cells. To eliminate any contribution from those fibrils, live cells were incubated with 
a sterile solution of the vital dye Trypan Blue, which quenches green fluorescence 
through an energy-transfer mechanism [295]. Since Trypan Blue cannot penetrate 
live cells, only the aggregates outside the cells will be quenched, without affecting the 
internalized ones. We performed several trials in order to optimize both the 
concentration of Trypan Blue and the incubation time according to the sensitivity of 
our cell lines (data not shown). 





Figure 3.6. Immunofluorescence data of internalized tau K18-488 fibrils in N2a cells at different 
timepoints. N2a cells were incubated with (A) 0.5 µM or (B) 2 µM of tau K18-488 fibrils for 24, 48 and 
72 hours. Images were acquired as series of Z-stacks and the analysis was carried out in 3D. Panels 
A and B show the XY projection of one of the central sections of the stack. White arrows in panel A 




N2a cell line Positive cells (%) 
 Tau K18 0.5 µM Tau K18 2 µM 
24 hours ~ 55 % 100% 
48 hours ~ 80% 100% 
72 hours 100% 100% 
 
Table 3.2. Quantification of N2a cells positive for tau K18 aggregates, expressed as a 
percentage. 
 
Tau fibrils are easily taken up by N2a cells after one day of incubation, and the 
internalization rate seems to be dependent on the concentration of the exogenous 
material. Indeed, after 3 days in contact with the fibrils all analysed cells had 
internalized the aggregates, whereas after 24 hours only cells incubated with the 
higher concentration of fibrils were 100% positive. When a lower concentration was 
used, the uptake increased over time both in terms of number of positive cells and of 
internalized fibrils. 
 
Given these results, we decided to use 2 µM as the final concentration of tau K18 
fibrils for all the experiments described in this work.  
 
3.4. The cellular prion protein interacts with tau K18 fibrils and facilitates their 
internalization 
 
Previous works reported that PrPC can act as a receptor for ß-sheet enriched 
structures like amyloid-ß and synuclein, mediating their toxic effect through the 
activation of signalling cascades and, in the case of intracellular amyloids, also 
promoting their uptake by recipient cells. Since tau shares key features with the 
aforementioned amyloids, we hypothesized that PrPC might be involved also in the 
internalization and spreading of tau fibrils.  
Both for amyloid-ß and synuclein, the first step required for these events to take place 
is the binding of the extracellular aggregates to PrPC[205, 274]. Concerning tau, full-
length tau was described to bind to PrPC through the interaction of the microtubule 
binding domains of tau and the amino acids 23-91 of the prion protein [302]; however, 
no studies have been conducted using fibrillar forms. In order to verify our hypothesis, 
we first checked if a direct interaction exists between PrPC and tau K18 fibrils. We 
performed a pull-down assay, a variant of the classical co-immunoprecipitation in 
which one of the two proteins is used as a bait instead of the antibody. Figure 3.7 
(panel A) sums up the key steps of this procedure. Before the incubation with cell 
lysate, tau fibrils were chemically conjugated to the succinimidyl ester of biotin, 
similarly to what has been previously described for fluorescent labelling. This step is 





Figure 3.7. Direct interaction between tau K18 fibrils and the endogenous PrPC from N2a cells 
visualized by pull-down assay. (A) Sonicated tau K18 fibrils were chemically conjugated to NHS-
biotin and subsequently incubated with N2a cell lysate overnight at 4°C to eventually form a complex. 
The day after, tau K18 fibrils were pulled down using streptavidin beads, and the precipitated samples 
were run on SDS-PAGE and blotted for PrPC detection. (B) Western Blot of pulled down samples. Lane 
1: K18 fibrils only; lane 2: N2a lysate only; lane 3: K18 fibrils and cell lysate. The membrane was probed 
with human anti-PrPC antibody D18. (C) Western Blot of input samples probed with anti-PrPC D18 and 
(D) with anti-biotin to visualize tau K18 fibrils. Lane 4: K18 fibrils only; lane 5: N2a cell lysate only; lane 
6: K18 fibrils and cell lysate. 
 
When we probed the pulled-down samples for PrPC by Western Blotting, we observed 
that the typical three-bands pattern was visible only when both binding partners were 
present. Although the signal coming from the pulled-down sample was fainter than its 
corresponding input, meaning that not all the PrPC binds to the fibrils, it indeed 
confirmed our hypothesis of a direct interaction taking place between the two proteins. 
This result was somehow expected, as the binding site on tau had been mapped on 
the microtubule binding domain.  
Afterwards, we moved on to evaluate if any differences in the internalization of the 
fibrils occurred between N2a and N2aKO. According to the results obtained in the 
experiments described in 3.2, both N2a and N2aKO were treated with 2 µM of tau 
K18-488 fibrils for 24 hours, and then processed for confocal microscopy analysis. 
Figure 3.8 shows two representative images for both cell types. Like in the previous 
experiments, we collected multiple sections along the z-axis to reconstruct the whole 
cellular volume, which can be visualized either in 2D, with orthogonal planes (panels 





Figure 3.8. Representative images of immunofluorescence data collected to evaluate the uptake 
of tau K18 fibrils in neuroblastoma cells. (A) and (C) show one of the central sections of the whole 
Z-stack of N2a and N2aKO, respectively. All the three orthogonal planes (XY, XZ, YZ) are displayed. 
(B) and (D) show the 3D reconstruction of N2a and N2aKO cells, respectively. 3D volumes are 
reconstructed by the algorithm of NIS Elements software based on the sections that were collected. 
Fibrils are represented by green spots; those internalized appear less bright in the 3D representation, 
and sometimes are not visible due to the density of the cell bodies.  
 
A good degree of internalization was observed for both N2a and N2aKO, with almost 
100% of the cells showing green puncta inside their cell bodies. However, when we 
evaluated the number of internalized aggregates, we noticed that N2a cells 
expressing PrPC take up around 60% more fibrils compared to N2aKO (Figure 3.9, 
panel A). We calculated an average uptake of 73 ± 40 fibrils for N2a cells and 46 ± 27 
for N2aKO. We also correlated the number of internalized fibrils with the cell volume, 
mainly to see if bigger cells actually take up more amyloids (Figure 3.9, panels B and 
C). There is indeed a direct and moderate correlation between the two parameters, 
as indicated by the Pearson’s coefficients calculated for both cell types. However, the 
average cell volume calculated is very similar, and the majority of both N2a and N2a 
KO stay between 500 and 1000 µm3, ruling out the possibility that different phases of 





Figure 3.9. Uptake of tau K18 fibrils in neuroblastoma cells. (A) Box and whiskers plot showing the 
distribution of the number of internalized fibrils in N2a and N2aKO cells. Numbers on top of the whiskers 
indicate the average number of internalized aggregates. A total of four hundred cells were counted in 
blind in three independent experiments. Data were evaluated with unpaired T-test with Welch’s 
correction. Statistical analysis is indicated as: * = p <0.05, ** = p< 0.01, *** = p<0.001. (B) and (C) 
Correlation between cell volume and the number of internalized fibrils per cell in N2a and N2a KO. For 
both cell types a direct correlation exists, and can be defined as “moderate correlation” according to 
Pearson’s coefficient. 
 
These data clearly indicate that the presence of PrPC on the cell membrane, although 
not mandatory for the entrance of tau K18 fibrils, greatly promotes the uptake process. 
The precise mechanism underpinning this phenomenon is not yet fully understood, 
but it probably involves a step of energy-dependent endocytosis. To confirm this idea, 
we compared the internalization rate of tau K18 fibrils in both cell types at two different 
temperatures: at 37°C, the physiological temperature at which cellular processes 
occur, and at 4°C, when all energy-dependent processes are inhibited, including 
endocytosis. While the concentration of the fibrils was the same as before (2 µM), the 
incubation time was reduced to 6 hours in order to perform the experiment at 4°C 






Figure 3.10. Tau K18 internalization is energy-dependent. 2D representative images of 
immunofluorescence data on tau internalization by N2a and N2aKO at 37°C (A) and 4°C (B). The 
analysis was carried out in 3D on series of multiple z-sections. The images presented in these panels 





Percentage of cells positive for tau K18 
aggregates 
N2a N2a KO 
37°C 80%  43% 
4°C Less than 1% Less than 1% 
 
Table 3.3. Quantification of N2a cells positive for tau K18 aggregates at 37°C and at 4 °C, 
expressed as a percentage.  
 
The data confirm the aforementioned time-dependency of tau uptake; indeed, after 6 
hours of treatment only 80% of N2a cells showed fibrils in their cell bodies, while in 
the previous experiments where the incubation time had been prolonged to 24 hours, 
100% of cells were positive for aggregates. Significantly fewer N2aKO cells had 
internalized tau fibrils (43%), suggesting that the PrPC-mediated mechanism plays a 
role in the early phases of the uptake process. When the incubation temperature was 
lowered to 4°C, we observed an almost complete inhibition of the uptake in both cell 
types regardless of their genetic background. Indeed, at this temperature the number 
of positive cells was comparable between N2a and N2aKO, meaning that whatever 
internalization pathway is mediated by PrPC, it is not active when energy-dependent 
mechanisms are blocked.  
 
We conclude that the cellular prion protein might act as a receptor for tau aggregates 
and facilitates their entrance into cultured cells through a direct binding and a 
subsequent endocytosis-mediated pathway. 
 
3.5. Tau K18 fibrils induce an increase of the endogenous prion protein  
 
The discovery of the important role of PrPC in the internalization of tau amyloids opens 
the question if this mechanism can be in some way over-activated by the fibrils 
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themselves, in order to sustain their spreading. To test this, we analysed the effect of 





Fig. 3.11. Effect of tau K18 fibrils on PrPC level in N2a cells at different timepoints. (A) Western 
blot analysis of N2a cells treated with 2 µM of tau K18 fibrils for 24, 48 and 72 hours and (B) of the first 
passage of N2a treated for 72 hours. Membranes were probed with human anti-PrP antibody D18. 
Each lane was loaded with 50 µg of total proteins. (C) The quantification of three independent 
experiments is shown in the graphs. Data are represented as the percentage of total PrP relative to ß-
actin, which is an internal loading control. PrPC levels of control cells have been normalized to 100. 
The histograms represent the mean ± SD. Data were evaluated by unpaired T-test. Statistical analysis 
is indicated as: n.s.= not significant; *= p<0.05; **= p<0.01; ***= p<0.001.  
 
After 72 hours of incubation with tau fibrils, we reported an increase of around 60% of 
the PrPC level in N2a cells (Figure 3.11, panels A and C). This effect seems to be 
dependent on the presence of the aggregates in the culture medium, because as soon 
as treated cells are passaged and kept in fibrils-free medium, PrPC level is again equal 
to that of control cells (Figure 3.11, panel B).  
We hypothesize that tau fibrils might act either at the RNA level, by increasing the 
transcription of the Prnp gene, or at the protein level, e.g. impairing the degradation 
of PrPC. Therefore, we isolated total RNA from control and treated N2a cells and 
performed a RT-PCR analysis (Figure 3.12). The results showed that there is no 
upregulation of Prnp transcription following 72 hours of incubation with tau K18 fibrils, 




Figure 3.12. RT-PCR analysis of Prnp expression levels on control and treated N2a cells. (A) 
Average values with SD of absolute CTs among the samples for Prnp and GAPDH genes. Every 
sample was analysed in duplicate. (B) Relative expression levels of Prnp gene normalized against 
GAPDH in control and K18-treated cells. The relative expression in control cells has been normalized 
to 1.  
 
After having established that the increase in PrPC level is a consequence of the 
addition of exogenous tau fibrils, we wondered if this phenomenon might be in some 
way related to the role of the prion protein in the internalization of the amyloids. 
Specifically, tau fibrils could exploit the higher amount of PrPC exposed on the cell 
surface to increase their internalization rate. To verify this, we used 
immunofluorescence to evaluate if more PrPC was transported to the cell membrane 
as a consequence of the treatment with tau aggregates (Figure 3.13). As a positive 
control to assess the validity of the experimental method, we used chlorpromazine, a 
drug that has been shown to reduce the levels of PrPC on the cell membrane (data 





Figure 3.13. A 72 hours exposure to tau K18 fibrils increases the levels of PrPC on the cell 
membrane of N2a cells. (A) Representative immunofluorescence images of untreated and treated 
N2a at three different timepoints. Membrane staining for PrPC was performed at 4°C on alive cells 
using the W226 antibody. The magnified sections show a visible difference in the fluorescence intensity 
associated to PrPC between control cells and cells treated for 72 hours. (B) Scatter plot of the intensity 
of the PrP-associated membrane staining of treated N2a compared to control cells. The intensity 
values, which correlates with the levels of PrP on the membrane, is reported as the ratio between the 
average intensities of treated and control cells for each timepoint. Controls have been normalized to 1. 
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The three values represent three independent experiments, in which 700 cells for each condition were 
analysed. Data have been evaluated with unpaired T-test. Statistical analysis is indicated as: n.s.= not 
significant; *= p<0.05; **= p<0.01; ***= p<0.001. 
 
As already observed in the immunoblot analysis, PrPC levels increase after 72 hours 
of incubation with tau aggregates. The quantification of membrane staining confirms 
that at least a part of the protein in excess is localized on the cell membrane (Figure 
3.13, panel B); however, it is not clear if this is due to an impaired recycling, with the 
consequent retainment on the membrane, or to the transportation of newly 
synthesized protein to the surface. Be it as it may, a higher amount of PrPC exposed 
outside the cells might result in more extracellular tau fibrils gaining cell entrance. 
Figure 3.14 shows a comparison of the number of fibrils internalized by both N2a and 
N2aKO after 24 and 72 hours of treatment. 
 
 
Figure 3.14. Quantification of internalized fibrils after 24 hours and 72 hours of treatment. 
Numbers on top of the whiskers represent the average number of internalized fibrils. Data were 
evaluated with unpaired T-test with Welch’s correction. Statistical analysis is indicated as: * = p <0.05, 
** = p< 0.01, *** = p<0.001. 
 
We observed that the internalization rate in N2a cells increases of around 50% when 
tau fibrils are left in the culture medium for three days. To rule out the possibility that 
this difference is due to other uptake mechanisms acting independently of PrPC, we 
conducted the same analysis on N2aKO cells. In this case the increase in the uptake 
was very modest, around 15%. Hence, the stronger effect observed in N2a must be 
connected with the presence of the prion protein on the membrane, suggesting that 
our hypothesis of tau fibrils taking advantage of the excess PrPC to enter the cells 
might actually prove true.  
 
3.6. Targeting PrPC reduces the internalization and the spreading of amyloids 
 
All the results reported so far point towards the involvement of PrPC in a novel 
receptor-mediated internalization pathway of tau fibrils. Therefore, we investigated if 
the targeting of specific domains of PrPC with antibodies might impair this mechanism 
and reduce the spreading of the pathology. Immunotherapy against the prion protein 
already proved successful in reducing the tau-mediated inhibition of long-term 
potentiation in mice inoculated with soluble tau aggregates [303]. To shed light on the 
molecular mechanisms underlying the phenotypic effects observed in vivo, we 
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quantified the internalized aggregates in N2a cells that had been subjected to pre-
treatment with anti-PrPC antibodies. Three different antibodies were tested: POM12, 
that targets the octarepeat regions in the N-terminus of PrPC; POM3, which is directed 
against the hydrophobic domain and specifically to the non-octarepeat region; and 
POM4, which recognizes a discontinuous and conformational epitope composed of a 
very C-terminal part of the protein and a portion spanning amino acids 121-134 




Figure 3.15. Three antibodies of the POMs series target distinct domains on PrPC. The structure 
of the prion protein has been modified from [206].  
 
The experiments on tau fibrils internalization and the subsequent quantification were 
conducted as described in sections 3.2 and 3.3. Before the addition of the fibrils, N2a 
cells were incubated with each one of the three antibodies for 1 hour, so that the 
antibody could bind to PrPC. We checked the binding of the antibody by 
immunofluorescence prior to perform the actual experiment (data not shown). We 
chose to use an antibody concentration of 15 µg/mL (80 nM), as it proved to be 
sufficient to target the majority of PrPC in N2a cells and inhibit PrPSc replication [304].  
 
 
Figure 3.16. Targeting PrPC reduces the uptake of tau K18 fibrils. Box and whiskers plots 
representing the distribution of internalized fibrils in N2a cells treated only with tau K18 fibrils and in 
N2a that were pre-treated with different anti-PrPC antibodies. Numbers on top of the whiskers indicate 
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the average number of internalized fibrils. Data were evaluated with unpaired T-test. Statistical analysis 
is indicated as: n.s.= not significant *= p<0.05; **= p<0.01; ***= p<0.001.  
 
The targeting of different domains on PrPC produced distinct and specific effects on 
the internalization rate of tau K18 fibrils (Fig. 3.16). Indeed, POM12 binds to a region 
that is known to be involved in the interaction with ß sheets-enriched amyloids. By 
impairing the docking of tau fibrils to PrPC, POM12 blocks this receptor-mediated 
endocytic pathway and reduces the uptake of the aggregates. A similar effect is 
observed upon treatment with POM3, whose epitope (the non octarepeat region 
spanning amino acids 95-100) was not considered to play a role in tau – PrPC binding 
according to previous studies [302]. Yet, it is possible that the hydrophobic domain 
might actually participate in the binding of fibrillar species of tau but not of the 
monomers; as its name says, this region of PrPC is highly hydrophobic and could 
interact with the ß sheets of the amyloids through non-specific hydrophobic effects. 
Another hypothesis sees POM3 acting as a steric hindrance that physically renders 
the binding site on the N-terminus inaccessible to tau fibrils. In both cases, a proper 
combination of the two antibodies in a single administration might end up in a further 
lowering of the internalization.  
On the other hand, POM4 did not produce any significant effect on tau uptake. 
However, as the C-terminal domain of PrPC is structurally very complex, we cannot 
exclude the hypothesis of its involvement in the internalization pathway, which might 
occur through a different epitope than the one targeted by POM4. Further experiments 
with antibodies targeting other regions on the globular domain could identify more 
sites that take part to this process. 
 
3.7. Exogenous tau K18 fibrils decrease PrPSc levels in prion infected ScN2a 
cells 
 
ScN2a are cells persistently infected with prions. In this work, we used two types of 
ScN2a, propagating either the RML or the 22L prion strains. Both strains have 
undergone adaptation in murine cells, but are considered to be unrelated, as RML 
derives from drowsy goat scrapie and 22L from sheep scrapie [305].  
First, we focused on ScN2a RML cell lines and we evaluated the effect of tau K18 
fibrils on the endogenous levels of PrPSc. Our group already reported that both non-
sonicated and sonicated synuclein fibrils reduce the amount of prions in scrapie-
infected cell lines[205]. We therefore wondered if this mechanism can be generalized 
to other ß sheet-enriched amyloids, independently of the protein identity.  
Figure 3.17 (panel A) shows the PrPSc levels after incubation of ScN2a RML with 2 
µM of tau K18 fibrils at three different timepoints (24, 48 and 72 hours). PrPSc levels 
were analysed by immunoblotting before and after proteolysis with proteinase K (20 






Figure 3.17. Western blot analysis of PrPSc in ScN2a RML cell lysates after treatment with tau 
K18 fibrils. (A) Following the treatment with tau K18 aggregates, total PrP and PK-resistant PrPSc 
proteins were separated by SDS-PAGE and detected with anti-PrP Ab (W226). β-actin is a loading 
control. “K18” indicate the treatment with 2 µM of tau fibrils. (B) Tau fibrils present in the cell lysate of 
ScN2a RML treated for 72 hours were subjected to proteinase K digestion and detected with anti-4 
repeat tau antibody RD4.  
 
The results clearly indicate that tau K18 fibrils have the ability to promote the 
clearance of prion aggregates inside cells, supporting the hypothesis of a mechanism 
mediated more by the abundance of specific conformational structures rather than by 
sequence requirements. PrPSc elimination however seems to be a quite slow process,  
as the decrease in the signal of proteinase K-resistant material started to be observed 
only after 72 hours of incubation with the exogenous aggregates. This is consistent 
with what reported in the previously mentioned work [205], where the exposure of 
ScN2a RML cells to synuclein aggregates lasts for 96 hours. The addition of fibrils 
greatly reduced the scrapie load, while in control cells a characteristic pattern of N-
terminally truncated fragments of di-, mono- and unglycosylated PrP was observed, 
with a prevalence of the monoglycosylated band. 
Moreover, we found PK-resistant forms of tau K18 fibrils in cell lysates of ScN2a 
treated for 72 hours (Figure 3.17, panel B). Such observation implies that tau fibrils 
are not easily degraded by the host cells, and therefore they are free to act on the 
molecular pathways involved in maintaining the endogenous levels of PrPSc.  
Next, we investigated if the clearance of prions enhanced by tau K18 is dependent on 
the presence of the aggregates in the culture medium. According to the previous 
experiment, we chose to use 72 hours as incubation time (Figure 3.18). This time we 
tested also the effect of monomeric tau on scrapie levels. While fibrils were able to 
efficiently clear prions, although not completely, monomeric-treated samples showed 
a pattern of PK-resistant bands very similar to that of control cells both in intensity and 
number of bands. This further corroborates our hypothesis of the predominant role of 
ß sheet amyloids in the prion clearance.  
The reduction of PrPSc seems to be affected, at least in part, by the presence of tau 
K18 fibrils in the culture medium. Indeed, although tau K18 species were removed 
from the cell culture medium after passage p0, scrapie levels remained low after 2 
passages (Figure 3.18 panel A). Control cells and cells treated with tau K18 fibrils 
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were kept in culture for additional passages to monitor the clearance, but after 
passage 3 the scrapie levels of treated cells rose again to the initial level (Figure 3.18, 




Figure 3.18. Western blot analysis of PrPSc in ScN2a RML cell lysates after treatment with tau 
K18 fibrils. Following the treatment with tau K18 aggregates, total PrP and PK-resistant PrPSc proteins 
were separated by SDS-PAGE and detected with anti-PrP Ab (W226). β-actin is a loading control. “K18 
mono” and “K18 fibr” indicate the treatment with 2 µM of monomeric tau and tau fibrils respectively. (A) 
Total PrP and PrPSc of ScN2a from passage 0 to passage 2. (B)  Total PrP and PrPSc of ScN2a from 
passage 3 to passage 5.  
 
In order to try to achieve a complete clearance of PrPSc, we prolonged the incubation 
with tau K18 fibrils at passage 0 up to 6 days; however, a faint but detectable signal 
remained along all passages, suggesting that an acute treatment is not sufficient to 
eliminate prions from the cells (Figure 3.19). A chronic administration would probably 




Figure 3.19. Western blot analysis of PrPSc in ScN2a RML cell lysates after treatment with tau 
K18 fibrils. Following the treatment with tau K18 aggregates for 6 days, total PrP and PK-resistant 
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PrPSc proteins were separated by SDS-PAGE and detected with anti-PrP Ab (W226). β-actin is a 
loading control.  
 
In physiological conditions, PrPC is subjected to proteolytic processing that produces 
biologically active fragments. The processing of the prion protein is thought to 
influence not only the course of prion disorders, but also other neurodegenerative 
diseases (463S). The so-called α-cleavage cuts the mature form of PrPC at residues 
K110/H111 or H111/M112 (human sequence) upstream of the hydrophobic sequence 
[306] and generates two fragments: the N-terminal soluble fragment N1, of 
approximately 11 kDa, and a C-terminal, membrane-attached fragment of around 18 
kDa, named C1. The α-cleavage strongly impairs the formation of prions by disrupting 
the PrP 109-122 region, which is critical for the conformational changes involved in 
both prion replication and toxicity [307]. The promotion of this specific processing 
might be a possible mechanism by which the treatment with tau K18 fibrils leads to 
the decrease of PrPSc. When ScN2a incubated with tau fibrils for 72 hours were 
subjected to enzymatic deglycosylation with PNGase F (Figure 3.20), we noticed that 
the 19 kDa band representing the PK-resistant core is less intense in tau-treated 
sample compared to the control. The fact that the band does not disappear completely 
is in agreement with the only partial PrPSc clearance observed in figure 3.17 (panel A, 
lane “K18 fibrils”, p0). In parallel to decrease of the PK-resistant band, in the K18 
treated sample there is the formation of a new band running at around 15 kDa that 
corresponds to the C1 fragment. We could confirm that this band is indeed the C1 
fragment by probing the membranes with two different antibodies that recognize either 
the C-terminal part of PrP (W226) or the N-terminus (SAF34). As observed in figure 





Figure 3.20. Electrophoretic pattern of PNGase F digested PrP in ScN2a control cells and cells 
treated with tau K18 fibrils. After PNGase F deglycosylation cell lysates were separated by SDS-
PAGE and PrP was immunoblotted with two Abs that recognize (A) C-terminal (W226), and (B) N-
terminal of the prion protein (SAF34). Solid black arrow shows the presence of C1 fragment recognized 
with C-terminal Ab, while the broken black arrow indicates the absence of the bands when the 
membrane was probed with N-terminal Ab. β-actin is a loading control. 
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Afterwards, we tested the strain specificity of tau K18-induced clearance of PrPSc by 
repeating the treatment on ScN2a infected with the 22L prion strain (Figure 3.21). 
Also, in this case we reported a strong reduction in the scrapie load after the 
administration of the fibrils, indicating that the mechanism activated by tau K18 is not 




Figure 3.21. Western blot analysis of PrPSc in ScN2a 22L cell lysates after treatment with tau 
K18 fibrils. Following the treatment with tau K18 aggregates for 3 days, total PrP and PK-resistant 




3.8. Activation of the degradation pathways is not involved in tau-mediated 
PrPSc clearance 
 
Our results so far show that the exposition of ScN2a cells propagating distinct prion 
strains to tau K18 sonicated fibrils results in the almost complete elimination of prions 
after a single administration; still, the molecular pathways activated by the amyloids 
to promote the clearance have not been identified.  
In general, exogenously added material can clear prions by two main mechanisms, 
and more often through their combination. Compounds or aggregated proteins can 
trigger the overactivation of degradation pathways (i.e. autophagolysosomal pathway) 
that are normally involved in the turnover of prions, or affect the activity of other factors 
that take part to prion formation. Alternatively, compound and/or aggregated proteins 
could bind either to PrPSc and destabilize it, or to PrPC and stabilize its native 
conformation, therefore inhibiting prion conversion. The observation that the potential 
differences in conformations characterizing the RML and 22L prion strains do not 
affect the clearance suggests that K18 fibrils might bind preferentially to the native 
PrPC.   
 
Nevertheless, we decide to evaluate if the cellular degradative mechanisms play a 
role in the elimination of PrPSc. Among these pathways, macroautophagy is known to 
be involved in the degradation of protein aggregates. ScN2a both untreated and 
treated with K18 fibrils for 72 hours were incubated with the macroautophagy inhibitor 
3-methyladenine (3-MA) for 16 hours and PrPSc levels were analysed by Western Blot 




Figure 3.22 Western blot analysis of PrPSc in ScN2a RML cell lysates after treatment with tau 
K18 fibrils and macroautophagy inhibitor 3-methyladenine. A) Western Blot analysis of ScN2a 
RML lysates treated with 10 mM 3-MA, 2 µM K18 fibrils or both. PK-resistant PrPSc proteins were 
separated by SDS-PAGE and detected with anti-PrP Ab (W226). β-actin is a loading control. 
(B)Western Blot analysis of LC3 levels in ScN2a untreated and treated with 10 mM of 3-MA. The black 
arrow point at the lower band representing the lipidated form of LC3, which is present in control cells 
and absent in 3-MA treated cells. (C) Quantification of two independent experiments. Data are shown 
as mean ± SDs. 
 
If autophagy was involved in the clearance of PrPSc, we would expect to have an 
increase in PrPSc levels after the incubation of ScN2a with 3-MA (Figure 3.22, panel 
A, first and second lanes); however, no difference could be detected after 16 hours of 
macroautophagy inhibition. As a control to verify the actual blockage of the autophagy, 
we analysed the conversion of LC3-I into LC3-II, which is recruited on the 
autophagosomal membrane and is considered to be an autophagic marker[308]. The 
treatment with 3-MA completely inhibited the conversion of LC3-I into LC3-II, therefore 
confirming the block of autophagy (Figure 3.22, panel C).  
We tested also the effect of 3-MA on K18-treated samples, since the autophagic 
pathway could be activated to specifically eliminate the exogenous fibrils and result in 
the simultaneous, unpredicted clearance of prions as a side effect. If this were true, 
the prion load would be higher after the inhibition of macroautophagy. After PK 
digestion, we observed that the PrPSc levels in the samples treated with only K18 and 
with both K18 and 3-MA were almost the same (Figure 3.22, panel A, third and fourth 
lanes). We then concluded that the macroautophagic pathway inhibited by 3-MA is 
not involved in the tau-induced PrPSc clearance.  
 
Next, we wondered if lysosomes could be responsible for the observed decrease of 
prions, and so we evaluated this hypothesis by inhibiting the lysosomal function with 
NH4Cl. Ammonium chloride is a highly soluble salt that has been reported to inhibit 
lysosomal activity by increasing the pH, blocking the autophagosome-lysosome 
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fusion and interfering with the activity of the proteases (253-254Ludo).  We compared 
the PrPSc levels in control and K18-treated ScN2a both in presence and in absence 
of 10 mM NH4Cl (Figure 3.23).  
 
 
Figure 3.23. PrPSc clearance mediated by tau fibrils is only partially affected by the inhibition 
of lysosomal degradation. (A) Western Blot analysis of ScN2a RML lysates treated for 72 hours 
with 10 mM NH4Cl, 2 µM K18 fibrils or both. PK-resistant PrPSc proteins were separated by SDS-
PAGE and detected with anti-PrP Ab (W226). β-actin is a loading control. (B) Quantification of three 
independent experiments. Data are shown as mean ± SDs.  
 
The partial inhibition of lysosomal activity was confirmed by the increase of the prion 
load in ScN2a treated with NH4Cl compared to control ScN2a. However, the addition 
of the inhibitor to the cells treated with tau led only to a modest recover of the initial 
scrapie levels, which on the contrary should return to the initial state if lysosomes 
were involved. Although the three experiments performed show a similar trend, the 
differences between samples treated with NH4Cl and the control were not statistically 
significant. Therefore, we concluded that although a contribution of the lysosomal 
pathway cannot be completely ruled out, it is not the major mechanism by which tau 























DISCUSSION AND CONCLUSIONS 
 
 
The cellular prion protein PrPC is mostly known for its unique role in the pathogenesis 
of prion disorders, where it converts into a misfolded, aggregation-prone conformer 
termed PrPSc that is the key player of these diseases. A decade ago, Strittmatter and 
colleagues have reported that PrPC binds Aβ oligomers and transduces their toxicity 
[284]. Although that report generated a significant amount of controversy [309], it is 
now generally accepted that at least in some cases PrPC may indeed mediate some 
effects of Aβ oligomers. Moreover, PrPC is able to promote the internalization of 
synuclein fibrils in neuroblastoma cell lines [205]. 
All these studies prove indeed that PrPC might mediate the neurotoxicity of diverse 
pathogenic protein aggregates by acting as a membrane receptor for their 
internalization and/or as a transducer of their associated neurotoxicity through 
activation of metabotropic glutamate receptors. Indeed, several neurodegeneration-
related proteins like amyloid ß, synuclein and tau appear to share key features with 
the prion protein, such as the propensity to assume aberrant conformations and 
trigger the aggregation of their physiological counterpart by recruiting the soluble 
protein and promoting their misfolding through physical monomer-monomer 
interactions. Proteins that possess these characteristics are referred to as “prion-like 
proteins”, and their corresponding diseases often show a typical pattern of 
progression that recalls the diffusion of prion diseases through the brain.  
Tauopathies are a group of progressive neurodegeneration disorders caused by the 
accumulation and spreading of aggregated isoforms of the protein tau. Except for 
Pick’s disease, the hallmark of all the other tauopathies is the deposition of the tau 
isoforms with four repeated microtubule binding domains in specific cell types and 
brain regions. In this work, we took advantage of a truncated 4R construct of tau 
(called K18) which is often used as a model for the study of this class of tauopathies. 
K18 fragment readily aggregates in vitro to form ß sheet-enriched amyloids that are 
taken up by cultured cells through many mechanisms. As already shown for synuclein 
fibrils, the prion protein might be involved in one of the internalization pathways. In 
this section, our results concerning the role of the prion protein in the uptake of tau 
fibrils and the effect of the internalized aggregates on both PrPC and PrPSc will be 
discussed. 
 
4.1. PrPC acts as a receptor to facilitate the entrance of tau fibrils in cultured 
cells 
 
The cellular prion protein has been shown to interact with various neurodegeneration-
related amyloids through a binding between its unstructured N-terminus and the ß 
sheet-enriched domains of the exogenous fibrils. As this interaction was reported both 
for synuclein and amyloid-ß, it seems plausible to posit that it might be mediated by 
the presence of specific secondary structure elements rather than by sequence 
identities. Therefore, we hypothesized that a similar mechanism might be 
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underpinning also the spreading of tau fibrils. The use of K18 fragment as a model of 
AD has been recently questioned due to the different arrangement of the residues in 
the K18 fibrils compared to brain-purified ones [83]; however, reports indicating that 
the interaction with PrPC seems to be dependent on major structure conformations 
like the amount of ß sheets and not on minor residue arrangements convinced us that 
K18 fragment might prove useful to shed light on the involvement of the prion protein 
in the onset of tauopathies. 
First, we showed that a direct binding between PrPC and sonicated tau fibrils is indeed 
occurring. This is the first mandatory step in the cascade of events that might lead to 
a PrPC-dependent internalization, and although there is proof of the interaction of the 
prion protein with monomeric full-length tau in the literature [302], no experiments had 
been performed so far using synthetic aggregates. The choice of subjecting tau fibrils 
to a brief cycle of sonication (5 minutes) is motivated by the fact that during the 
aggregation, nascent amyloids tend to stick to each other and form sorts of big 
plaques that are not easily internalized by the cells. Sonication breaks these big 
aggregates and allows a better interaction of the single fibrils with their potential 
receptors, including PrPC.  
In order to evaluate the contribution of a putative receptor, exogenous fibrils must be 
taken up by the chosen cell line without the need for a chemical transducer. 
Spontaneous uptake of tau fibrils from the cell culture medium has already been 
shown for some cell lines (HEK293, QBI-293) [247, 254, 310] and for primary neurons 
[301]. When added to the culture medium of our murine neuroblastoma cell line, tau 
fibrils were internalized with a rate that depends both on the duration of the incubation 
and on the initial concentration of the aggregates. Cultures treated with low 
concentrations of tau fibrils required up to three days in order for all the cells to show 
aggregates in the cell cytoplasm, while at the higher concentration of 2 µM an 
incubation of 24 hours proved sufficient. These specific requirements are strictly 
related to the cell type used, as the time needed for the internalization varied from 3 
days in HEK293T to 6 days in primary neurons, and as such they have to be carefully 
addressed before setting up further experiments.  
 
Afterwards, we evaluated the role of the prion protein in the spreading of tau pathology 
by comparing the number of internalized tau amyloids between cells that express 
PrPC on the cell surface (N2a) and cells from which Prnp (the gene encoding PrPC) 
was removed (N2a KO). To visualize the internalized fibrils, we chemically conjugated 
tau amyloids to a fluorophore as described in [295]. Succinimidyl esters bind to all 
primary amines of proteins and oligonucleotides with no distinction, therefore only 
pure synthetic fibrils can be conjugated without the risk of undesired signal coming 
from other material. The use of fluorescently-labelled amyloids allows a direct and 
precise visualization of the aggregates both in live cell imaging and in classical 
immunofluorescence experiments on fixed cells, making the use of antibodies 
unnecessary and thus reducing the background signal usually associated with 
immunolabelling. Moreover, quantification of internalized fibrils results in a more 
precise counting, especially when the aggregates have undergone a round of 
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sonication that by breaking randomly along the length of the fibril, might destroy the 
epitope recognized by the antibody. 
 
The results obtained suggest that PrPC plays a role in the endocytosis of tau fibrils, 
although its presence is not mandatory. N2a KO cells, even if deprived of PrPC, were 
able to internalize a discrete number of fibrils, consistently with previous reports of 
multiple mechanisms going on at the same time and independently from each other. 
However, when the prion protein was present, the number of internalized fibrils almost 
doubled, meaning that the PrPC-mediated pathway gives indeed a strong contribution 
to this process.  
Most intriguingly, we discovered that the interaction between PrPC and tau fibrils has 
mutual effects on both partners; while the former acts as a sort of receptor, the 
presence of tau aggregates leads to an increase of the cellular level of the prion 
protein, which is re-localized mainly on the plasma membrane where it could perform 
again its receptor activity. According to our data, the excess PrPC is probably a result 
of an impairment in the normal recycling pathway caused by tau fibrils, as no changes 
in total PrP content of the cells were detected. 
Although this phenomenon might be a simple side-effect of the interaction and 
subsequent internalization of the aggregates, we deem it likely that tau fibrils are 
boosting their own spreading by increasing the number of receptor molecules on the 
cell surface. A similar hypothesis has been proved true in the case of intercellular 
transfer of tau amyloids through tunneling nanotubes, where extracellular tau species 
(monomers and fibrils) activated the formation of new nanotubes and therefore 
facilitated fibrillar tau transport between neurons [272]. On the other hand, it has been 
shown that protein aggregates (tau and synuclein) are trafficked in early endosomes 
and lysosomes after the internalization [205, 242, 311]. The need of the cell to deal 
quickly with a big amount of exogenous and potentially dangerous material might lead 
to a clogging of the whole degradation system, with subsequent impact on the normal 
turnover of the endogenous proteins. Indeed, a similar effect on PrP levels has been 
reported also after treatment with synuclein fibrils, although the localization of the 
excess protein was not investigated. Alternatively, the binding of the amyloids to the 
PrPC on the cell membrane might simply impede its internalization and retain the 
protein in its position, therefore leading to a general increase as the newly synthesized 
protein follows its normal pathway all the way up to the surface.  
 
The potential function of PrPC in binding and mediating cell-to-cell spread of tau 
amyloids points to an intriguing new function of PrPC and opens a very interesting 
field of research. Moreover, the identification of such a receptor provides a potentially 
valuable target for pharmacological intervention.  
Immunotherapy has shown promising results against many neurodegenerative 
diseases [312]. In particular, passive immunization occurred when prion-infected cell 
lines were exposed to monoclonal anti-PrP antibodies (SAF32, SAF61, 6H4), 
resulting in a decrease of PrPSc levels as previously observed also in vitro [313]. When 
applied to animal models of prion disorders, anti-PrP antibodies could block the 
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spread of prions from the periphery to the central nervous system [314]. Passive 
immunotherapy configures as the safest option in antibody-based treatments of prion 
disorders, as an active immunization against the prion protein might elicit a strong 
inflammatory response in the brain.  
Nevertheless, the number of diseases that might possibly benefit from a PrPC-directed 
immunotherapy is not limited only to prion disorders. Amyloid ß-induced cognitive 
deficits in AD, like memory impairment and suppression of synaptic plasticity, are 
triggered by a signaling cascade that starts with the binding of the oligomers to the 
prion protein, and thereby they can be rescued by pre-treatments with anti-PrPC 
antibodies that impede the docking of Aß oligomers [315-318]. A recent publication 
pointed out that the targeting of either the mid region or the N-terminus of PrPC might 
be effective also in abrogating the impairment of long-term potentiation caused by 
soluble aggregates of tau protein [303]. While this study focused mainly on the 
antibody-mediated recovery of normal brain functions in rats injected with synthetic or 
brain-derived tau fibrils, in this thesis we aimed at unraveling the exact molecular 
mechanisms underlying this phenomenon. In agreement with the in vivo data, we 
found that the average number of internalized tau fibrils was significantly lower in cells 
pre-treated with POM antibodies that targeted a portion of the N-terminal domain 
(POM12) and the hydrophobic domain (POM3). We are currently testing different 
treatment conditions as well as possible combinations of these two types of antibodies 
in order to maximize the inhibitory effect. 
On the contrary, the POM4 antibody that targets a region of the C-terminal domain 
did not produce any effect on the uptake of fibrils. Given that the globular domain of 
PrPC has a compact, well-defined and inflexible structure, we cannot rule out the 
possibility that it could also be involved in facilitating the entrance of tau fibrils, maybe 
through a different epitope that was not blocked by POM4.  
Taken together, our data provide the first mechanistic study of the role of the prion 
protein in the spreading of tau pathology and the molecular details underlying the 
ability of anti-PrPC antibodies to rescue tau-induced pathology.  
 
4.2. Tau K18 fibrils reduce PrPSc levels in prion-infected cell lines 
 
The incubation of ScN2a cell line with tau K18 fibrils for 3 days produced an almost 
total clearance of PrPSc after a single administration. Albeit the elimination of prions 
was not complete and could not be maintained over serial passages in fibrils-free 
medium, the PrPSc levels remained lower than those of control conditions for many 
days, suggesting that a second administration of tau fibrils might be able to fully 
abolish the prion load. Tau-mediated clearance does not seem to be affected by 
differences in the PrPSc conformation, as a similar reduction was observed for both 
RML and 22L prion strains.  
Anti-prion compounds, or aggregated proteins in this case, are able to diminish prion 
levels in scrapie-infected cell lines by following one of two main mechanisms of action, 
and sometimes the final result is achieved by a combination of these two pathways 
working at the same time. In the indirect mechanism, exogenous molecules promote 
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PrPSc elimination by over-activating the cellular degradation pathways such as the 
autophagolysosomal system, that in cells propagating prions are regulated to 
maintain a basal level of prion load. The activation could involve the organelles 
themselves, or it could focus on other proteins that take part to the degradation 
process. Alternatively, compounds can bind directly to either PrPC or PrPSc and inhibit 
prion conversion by depleting respectively the pool of the substrate or of the template. 
Evidence presented in this thesis suggest that this second event might be the most 
probable way through which the tau-mediated clearance of scrapie prions occurs, with 
tau fibrils binding preferentially to PrPC. In addition to having shown that K18 fibrils 
interact with the cellular form of the prion protein, the similar effects observed after 
the exposition of two different prion strains to tau aggregates led us to believe that 
PrPSc might not be the target. As the exact structure of PrPSc is poorly defined, the 
structural differences distinguishing the RML and 22L prion strains are not known, 
and could be so subtle not to impact the binding of K18 fibrils in a detectable manner. 
However, it comes more straightforward to hypothesize that the partner involved in 
the interaction is the physiological form PrPC.  
Our data, although preliminary, hint at a more complex mechanism of action for tau 
K18 fibrils than just binding to the PrPC. The analysis of the total PrP of ScN2a after 
deglycosylation, which allows for unambiguous identification of all products of PrP 
processing, revealed that K18 amyloids promote the α-cleavage of the PrPC with the 
formation of the fragment C1.  
This type of PrP processing is considered neuroprotective against prions, as the 
cleavage site is located inside the amyloidogenic sequence 109-122. This portion of 
the protein that spans the hydrophobic domain is postulated to acquire ß sheet 
structure and play a critical role in prion formation and toxicity. The α-cleavage occurs 
between amino acids 110/111 or 111/112 and disrupts this region, therefore 
preventing prion conversion. Two fragments are originated: the C1 fragment, whose 
functions are still debated but appear to be linked to the enhancement of apoptotic 
effects, and the neuroprotective fragment N1, which reduces the p53-dependent cell 
death. Most importantly, none of these two fragments is a substrate for prion 
conversion, and therefore the cleavage of PrP into these two peptides prevents prion 
accumulation. 
Despite these observations, we investigated also whether the cellular degradation 
pathways such as macroautophagy and lysosomal degradation are involved, at least 
partially, in tau-induced PrPSc clearance.  Macroautophagy proceeds through the 
formation of a double membrane structure called phagosome which engulfs the cargo 
that has to be degraded (like organelles or protein aggregates) and delivers it to the 
lysosomes [319]. Stimulation of autophagy is an efficient way to decrease the prion 
load in cell cultures [320, 321]. The compound we used to block the pathway, 3-
methyladenine, is one of the most commonly employed inhibitors of autophagy [322] 
and it acts on the phosphoinositide-3 kinases (PI3K) that catalyse the first step in the 
formation of the phagosome. We could not detect any effect of the treatment with 3-
MA on the PrPSc levels, independently on previous incubation with K18 fibrils. 
Although 3-MA has been recently questioned as an inhibitor because of its apparent 
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dual role in the modulation of autophagy [323], our data based on the treatments with 
this compound seem to exclude a role for macroautophagy in the clearance of prions, 
at least in our specific cell line. Indeed, several alternative pathways of PrPSc 
elimination have been reported, varying according to the cell type used and the forms 
of misfolded PrP (i.e. newly formed PrPSc, mature PrPSc, mutant PrP) [324]. Moreover, 
Goold et al. [325] proposed a new and interesting role for the UPS in PrPSc 
degradation, which might be a valid alternative to the pathways analysed in this thesis.  
Since both tau and synuclein fibrils have been reported to colocalize with lysosomes 
once they have been internalized, tau-induced clearance of prions might occur as an 
effect of the overactivation of the lysosomal system. As a first preliminary experiment, 
we performed an inhibition of the whole lysosomal environment by the treatment with 
NH4Cl, that increases the pH of the vesicles and impairs the activity of the enzymes. 
What we observed was just a mild recovery of normal prion levels in ScN2a treated 
with both K18 fibrils and NH4Cl, which made us think that the stimulation of the 
lysosomal activity is not the primary mechanism by which tau amyloids promote the 
decrease in PrPSc levels. We are currently assessing the effect of tau fibrils on the 
activity of the cathepsins known to have a role in prion degradation (cathepsins B, S 
and L).  
 
 
In conclusion, in this study we provided significant evidence of an important role for 
PrPC in mediating the internalization of exogenous tau fibrils, therefore contributing to 
the cell-to-cell spreading of the aggregates and to the onset of the pathology. 
Moreover, we successfully evaluated the potentiality of PrPC as a therapeutic target 
to inhibit the uptake of tau amyloids. The interaction between tau fibrils and the cellular 
prion protein seems to affect also the process of prion replication in prion-infected cell 
lines. This occurs probably through the inhibition of the mechanism of PrPC 
conversion into PrPSc, due to an increased rate α-cleavage of PrPC stimulated by the 
binding to tau fibrils. The role of endogenous degradation mechanisms could not be 
ruled out, although they play only a marginal role. These findings open new avenues 
in tauopathies and prion research, as well as potentially valuable targets for 
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